Long-term effects of AÎ²42 immunisation in Alzheimer's placebo-controlled phase I trial

Lancet, The

372, 216-223

DOI: 10.1016/s0140-6736(08)61075-2

Citation Report

#	Article	IF	Citations
2	Moving towards a vaccine. Nature, 2008, 454, 419-420.	13.7	41
3	A tale of two tilings. Nature, 2008, 454, 420-421.	13.7	11
4	Neuroscience: The plaque plan. Nature, 2008, 456, 161-164.	13.7	52
5	Amyloid-Î² immunisation for Alzheimer's disease. Lancet Neurology, The, 2008, 7, 805-811.	4.9	149
6	Pharmacotherapeutic targets in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2009, 13, 61-86.	1.6	50
7	DNA epitope vaccine containing complement component C3d enhances anti-amyloid-Î² antibody production and polarizes the immune response towards a Th2 phenotype. Journal of Neuroimmunology, 2008, 205, 57-63.	1.1	33
8	Inflammaging as a prodrome to Alzheimer's disease. Journal of Neuroinflammation, 2008, 5, 51.	3.1	258
9	Clinical immunotherapy trials in Alzheimerâ€™s disease. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 177-183.	0.5	4
10	Linking AÎ² and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis. Neuron, 2008, 60, 534-542.	3.8	465
11	Will anti-amyloid therapies work for Alzheimer's disease?. Lancet, The, 2008, 372, 180-182.	6.3	71
12	Amyloid-Î² vaccination for Alzheimer's dementia. Lancet, The, 2008, 372, 1381.	6.3	7
13	Amyloid-Î² vaccination for Alzheimer's dementia. Lancet, The, 2008, 372, 1381.	6.3	4
14	Preventing Alzheimerâ€™s Disease. CNS Drugs, 2008, 22, 887-902.	2.7	16
16	Consequence of AÎ² immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131, 3299-3310.	3.7	283
17	The Canine (Dog) Model of Human Aging and Disease: Dietary, Environmental and Immunotherapy Approaches. Journal of Alzheimer's Disease, 2008, 15, 685-707.	1.2	167
18	Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. Current Opinion in Psychiatry, 2008, 21, 555-561.	3.1	41
20	New Therapies in the Pipeline for AD â€" What's Promising, What's Not. Neurology Today: an Official Publication of the American Academy of Neurology, 2008, 8, 1.	0.0	0
21	Anti-Amyloid-Î² Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials. Journal of Alzheimer's Disease, 2008, 15, 555-569.	1.2	96

#	Article	IF	Citations
22	Non-Amyloid Approaches to Neuroprotection. CNS Spectrums, 2008, 13, 42-44.	0.7	0
23	The Effects of NOS2 Gene Deletion on Mice Expressing Mutated Human AÎ²PP. Journal of Alzheimer's Disease, 2008, 15, 571-587.	1.2	81
24	Diminished Amyloid-Î² Burden in Tg2576 Mice Following a Prophylactic Oral Immunization with a Salmonella-Based Amyloid-Î² Derivative Vaccine. Journal of Alzheimer's Disease, 2009, 18, 961-972.	1.2	20
25	Novel Pharmacotherapies for Alzheimer's Disease. Journal of the Korean Medical Association, 2009, 52, 1059.	0.1	10
26	Tratamiento de la enfermedad de Alzheimer: Rol de agentes neurotrÃ³ficos. Revista Chilena De Neuro-Psiquiatria, 2009, 47, .	0.0	1
27	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. Scientific World Journal, The, 2009, 9, 373-389.	0.8	24
28	Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?. Dementia E Neuropsychologia, 2009, 3, 188-194.	0.3	72
29	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Review of Neurotherapeutics, 2009, 9, 1413-1431.	1.4	120
30	Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid-Î². Journal of Alzheimer's Disease, 2009, 18, 729-750.	1.2	94
31	HLA-DR Alleles in Amyloid Î²-Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele. Journal of Immunology, 2009, 183, 3522-3530.	0.4	48
32	Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18367-18372.	3.3	225
33	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12145-12150.	3.3	171
34	Cinnamon Extract Inhibits Tau Aggregation Associated with Alzheimer's Disease In Vitro. Journal of Alzheimer's Disease, 2009, 17, 585-597.	1.2	131
35	AÎ² Immunotherapy Protects Morphology and Survival of Adult-Born Neurons in Doubly Transgenic APP/PS1 Mice. Journal of Neuroscience, 2009, 29, 14108-14119.	1.7	59
36	Genentech's new parADigm. Science-Business EXchange, 2009, 2, 300-300.	0.0	0
37	AÎ² Immunotherapy: Intracerebral Sequestration of AÎ² by an Anti-AÎ² Monoclonal Antibody 266 with High Affinity to Soluble AÎ². Journal of Neuroscience, 2009, 29, 11393-11398.	1.7	103
38	DNA Î²-Amyloid₁₋₄₂ Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model. JAMA - Journal of the American Medical Association, 2009, 302, 1796.	3.8	48
39	Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 774-784.	0.9	92

#	Article	IF	Citations
40	Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models. Inflammation and Allergy: Drug Targets, 2009, 8, 277-284.	1.8	83
41	Do amyloid-lowering strategies work clinically?. Therapeutic Advances in Neurological Disorders, 2009, 2, 3-6.	1.5	2
42	Amyloid deposits: Protection against toxic protein species?. Cell Cycle, 2009, 8, 1668-1674.	1.3	125
43	Immunotherapy for Alzheimer disease. MAbs, 2009, 1, 112-114.	2.6	2
44	Therapeutic Trends and Genetic Insights Highlighted in Noteworthy Papers in Dementia and Memory. Neurology Today: an Official Publication of the American Academy of Neurology, 2009, 9, 23-24.	0.0	0
45	Recent advance in immunotherapies for Alzheimer disease, with special reference to DNA vaccination. Hum Vaccin, 2009, 5, 373-380.	2.4	12
46	The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain. CNS and Neurological Disorders - Drug Targets, 2009, 8, 7-15.	0.8	49
47	Transglutaminase activation in neurodegenerative diseases. Future Neurology, 2009, 4, 449-467.	0.9	34
48	Immunotherapy for Alzheimerâ€™s disease. Immunotherapy, 2009, 1, 461-469.	1.0	4
50	Humanin; A Defender Against Alzheimers Disease?. Recent Patents on CNS Drug Discovery, 2009, 4, 37-42.	0.9	31
52	Is passive immunization for Alzheimer's disease â€˜alive and wellâ€™ or â€˜dead and buriedâ€™?. Expert Opinion on Biological Therapy, 2009, 9, 481-491.	1.4	28
53	In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology, 2009, 72, 1504-1511.	1.5	87
54	Microglial Activation in Alzheimers Disease. Current Alzheimer Research, 2009, 6, 554-563.	0.7	77
55	Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies. Current Alzheimer Research, 2009, 6, 446-450.	0.7	83
56	Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice. Journal of Neuroscience, 2009, 29, 4964-4971.	1.7	29
57	Biomarkers of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 128-140.	2.1	175
58	An amyloid-Î² protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 36, 425-434.	2.1	89
59	Cognitive impairment in the Tg6590 transgenic rat model of Alzheimerâ€™s disease. Journal of Cellular and Molecular Medicine, 2010, 14, 1816-1823.	1.6	24

#	Article	IF	Citations
60	Neuronal death in Alzheimerâ€™s disease and therapeutic opportunities. Journal of Cellular and Molecular Medicine, 2009, 13, 4329-4348.	1.6	97
61	Monitoring the amyloid beta-peptide in vivo â€“ caveat emptor. Drug Discovery Today, 2009, 14, 241-251.	3.2	10
62	Bridging the gap: From protein misfolding to protein misfolding diseases. FEBS Letters, 2009, 583, 2581-2586.	1.3	90
63	Alzheimer's disease: on the verges of treatment and prevention. Lancet Neurology, The, 2009, 8, 4-5.	4.9	27
64	Decorated plaques in Alzheimer's disease. Annals of Neurology, 2009, 65, 4-6.	2.8	3
65	Î²â€amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. Journal of Comparative Neurology, 2009, 513, 417-429.	0.9	33
66	Development of vaccination approaches for the treatment of neurological diseases. Journal of Comparative Neurology, 2009, 515, 4-14.	0.9	12
67	Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease. Drug Development Research, 2009, 70, 125-144.	1.4	33
68	Alzheimer â€“ Mechanismen und therapeutische AnsÃtze. Warum wir im Alter dement werden. Biologie in Unserer Zeit, 2009, 39, 92-100.	0.3	0
69	Recent advances in our understanding of neurodegeneration. Journal of Neural Transmission, 2009, 116, 1111-1162.	1.4	235
70	Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathologica, 2009, 117, 1-14.	3.9	422
71	Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica, 2009, 118, 53-69.	3.9	577
72	Microvasculature changes and cerebral amyloid angiopathy in Alzheimerâ€™s disease and their potential impact on therapy. Acta Neuropathologica, 2009, 118, 87-102.	3.9	256
73	Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 2009, 118, 5-36.	3.9	805
74	Alzheimer's disease and bloodâ€“brain barrier functionâ€”Why have anti-Î²-amyloid therapies failed to prevent dementia progression?. Neuroscience and Biobehavioral Reviews, 2009, 33, 1099-1108.	2.9	66
75	Life and Death of Microglia. Journal of NeuroImmune Pharmacology, 2009, 4, 371-379.	2.1	173
76	Biomarkers for Alzheimer's disease trials â€” biomarkers for what? A discussion paper. Journal of Nutrition, Health and Aging, 2009, 13, 334-336.	1.5	14
77	Development of AFFITOPE vaccines for Alzheimer's disease (AD) â€” From concept to clinical testing. Journal of Nutrition, Health and Aging, 2009, 13, 264-267.	1.5	119

#	Article	IF	Citations
78	Pharmaceutical treatment for cognitive deficits in Alzheimerâ€™s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology, 2009, 202, 15-36.	1.5	31
79	Timeâ€dependent insulin oligomer reaction pathway prior to fibril formation: Cooling and seeding. Proteins: Structure, Function and Bioinformatics, 2009, 77, 62-73.	1.5	43
81	Immunization in Alzheimer's disease: naÃ¯ve hope or realistic clinical potential?. Molecular Psychiatry, 2009, 14, 239-251.	4.1	37
82	Reduction of AÎ²42 in brains of transgenic APP<scp>swe</scp> mice by 2â€²â€chlorophenylaminophenylacetate. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 1099-1103.	0.9	1
83	The amyloid hypothesis for Alzheimerâ€™s disease: a critical reappraisal. Journal of Neurochemistry, 2009, 110, 1129-1134.	2.1	700
84	The Hygiene Hypothesis and Darwinian Medicine. , 2009, , .		23
85	Dramatic Shifts in Circulating CD4 but not CD8 T Cell Subsets in Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 91-103.	1.2	173
86	Reassessing the amyloid cascade hypothesis of Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2009, 41, 1261-1268.	1.2	318
87	Prevention of age-associated dementia. Brain Research Bulletin, 2009, 80, 315-325.	1.4	26
88	The Alzheimer's disease mitochondrial cascade hypothesis: An update. Experimental Neurology, 2009, 218, 308-315.	2.0	181
89	Protein aggregation as a paradigm of aging. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 980-996.	1.1	92
90	NMR studies reveal a novel mode for hFADD to bind with the unstructured hRTN3 which initiates the ER-stress activated apoptosis. Biochemical and Biophysical Research Communications, 2009, 383, 433-439.	1.0	5
91	Reduced oligomeric and vascular amyloid-Î² following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vaccine, 2009, 27, 1365-1376.	1.7	28
92	When should drug treatment be started for people with dementia?. Maturitas, 2009, 62, 230-234.	1.0	8
93	Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified Î²-amyloid peptides. Molecular Immunology, 2009, 46, 2524-2532.	1.0	2
94	Drug development for Alzheimer's disease: Where are we now and where are we headed?. American Journal of Geriatric Pharmacotherapy, 2009, 7, 167-185.	3.0	124
95	Microglial Physiology: Unique Stimuli, Specialized Responses. Annual Review of Immunology, 2009, 27, 119-145.	9.5	1,562
96	Medical bioremediation of age-related diseases. Microbial Cell Factories, 2009, 8, 21.	1.9	21

#	Article	IF	Citations
97	Why Did Tarenflurbil Fail in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2009, 17, 757-760.	1.2	65
98	Development of semagacestat (LY450139), a functional Î³-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2009, 10, 1657-1664.	0.9	151
99	Alzheimer's disease therapeutic research: the path forward. Alzheimer's Research and Therapy, 2009, 1, 2.	3.0	46
100	APOE-4 Genotype and Neurophysiological Vulnerability to Alzheimer's and Cognitive Aging. Annual Review of Clinical Psychology, 2009, 5, 343-362.	6.3	84
101	Disease-Modifying Approach to the Treatment of AlzheimerÊ¼s Disease. Drugs and Aging, 2009, 26, 537-555.	1.3	80
103	Telomerase and Human Disease: The Beginnings of the Ends?. Rejuvenation Research, 2009, 12, 333-340.	0.9	2
104	Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimer's Research and Therapy, 2009, 1, 6.	3.0	116
105	Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Progress in Brain Research, 2009, 175, 83-93.	0.9	74
106	Defining and labeling diseaseâ€modifying treatments for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 406-418.	0.4	59
107	Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. Alzheimer's and Dementia, 2009, 5, 340-347.	0.4	96
108	Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug Development. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 364-370.	1.3	136
109	Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. CNS Neuroscience and Therapeutics, 2009, 15, 358-374.	1.9	129
110	Time for a Change in the Research Paradigm for Alzheimer's Disease: The Value of a Chaotic Matrix Modeling Approach. CNS Neuroscience and Therapeutics, 2010, 16, 254-262.	1.9	9
111	Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658.	4.9	259
112	Dissecting Molecular Mechanisms in the Living Brain of Dementia Patients. Accounts of Chemical Research, 2009, 42, 842-850.	7.6	36
113	Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behavioural Pharmacology, 2009, 20, 330-336.	0.8	38
114	Brain-Derived Neurotrophic Factor Reverses Memory Loss and Cognitive Impairment in Animal Models of Aging and Alzheimer Disease. Neurology Today: an Official Publication of the American Academy of Neurology, 2009, 9, 20-21.	0.0	0
115	Neurobiology of cognitive disorders. Current Opinion in Psychiatry, 2009, 22, 546-551.	3.1	24

#	Article	IF	Citations
117	ã,·ãƒ³ãƒã,ã,¦ãƒ4ã€€ã,¢ãƒ«ãƒ„ãƒã,ãƒžãƒ¼ç—…ã®è¨ºæ–ä¨æ²»ç™‚,é–‹ç™ºã€€ã,ªãƒ¼ãƒãƒ¼ãƒ"ãƒ¥ãƒ¼. Clinical Neurology, 2009, 49, 8	0.0	0
118	6. Recent Progress of Alzheimer's Dementia. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 2305-2311.	0.0	1
119	Amyloid-Î², Tau, and Dementia. Journal of Alzheimer's Disease, 2009, 17, 729-736.	1.2	53
120	Regulated Proteolysis of RAGE and AÎ²PP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 865-878.	1.2	36
121	Current and Future Treatments for Alzheimer's Disease. CNS Spectrums, 2009, 14, 4-7.	0.7	8
122	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	0.9	492
124	Alzheimerâ€™s disease: from pathogenesis to novel therapeutic approaches. Therapy: Open Access in Clinical Medicine, 2009, 6, 259-277.	0.2	1
125	Vascular Factors in Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 859-864.	1.2	39
126	AD Vaccines: Conclusions and Future Directions. CNS and Neurological Disorders - Drug Targets, 2009, 8, 160-166.	0.8	11
127	Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention. CNS and Neurological Disorders - Drug Targets, 2009, 8, 144-159.	0.8	36
128	Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice. CNS and Neurological Disorders - Drug Targets, 2009, 8, 50-64.	0.8	76
129	Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy. CNS and Neurological Disorders - Drug Targets, 2009, 8, 128-143.	0.8	21
130	Quantitative and Mechanistic Studies of Aβ Immunotherapy. CNS and Neurological Disorders - Drug Targets, 2009, 8, 31-49.	0.8	46
131	Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial. CNS and Neurological Disorders - Drug Targets, 2009, 8, 88-97.	0.8	37
132	Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle. CNS and Neurological Disorders - Drug Targets, 2009, 8, 98-113.	0.8	12
133	Alternative Aβ Immunotherapy Approaches for Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2009, 8, 114-127.	0.8	40
134	Update on the Pharmacological Treatment of Alzheimers Disease. Current Neuropharmacology, 2010, 8, 69-80.	1.4	129
135	Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid Î² After a Single Administration of an Amyloid Î² Monoclonal Antibody in Subjects With Alzheimer Disease. Clinical Neuropharmacology, 2010, 33, 67-73.	0.2	172

#	Article	IF	Citations
136	AD BIOMARKERS YEARS BEFORE ONSET OF SYMPTOMS. Neurology Today: an Official Publication of the American Academy of Neurology, 2010, 10, 1.	0.0	0
137	Amyloid precursor protein and tau transgenic models of Alzheimerâ€™s disease: insights from the past and directions for the future. Future Neurology, 2010, 5, 411-420.	0.9	4
138	Alzheimer's Disease is Incurable but Preventable. Journal of Alzheimer's Disease, 2010, 20, 861-870.	1.2	91
139	Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?. Journal of Alzheimer's Disease, 2010, 19, 405-421.	1.2	26
140	Rethinking Alzheimer's Disease Therapy: Are Mitochondria the Key?. Journal of Alzheimer's Disease, 2010, 20, S579-S590.	1.2	47
141	Anti-Inflammatory Action of Donepezil Ameliorates Tau Pathology, Synaptic Loss, and Neurodegeneration in a Tauopathy Mouse Model. Journal of Alzheimer's Disease, 2010, 22, 295-306.	1.2	106
142	Amyloid-Î² Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. Journal of Alzheimer's Disease, 2010, 20, 637-646.	1.2	69
143	Immunization Therapy for Alzheimer Disease: A Comprehensive Review of Active Immunization Strategies. Tohoku Journal of Experimental Medicine, 2010, 220, 95-106.	0.5	60
144	Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?. Journal of Alzheimer's Disease, 2010, 22, 393-399.	1.2	72
149	Current therapeutic targets for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 711-728.	1.4	101
150	Galantamine-induced Amyloid-Î² Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2010, 285, 40180-40191.	1.6	145
151	Vaccination as a Therapeutic Approach to Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 17-31.	1.9	43
152	Alzheimer's Disease. New England Journal of Medicine, 2010, 362, 329-344.	13.9	4,116
153	Î²-amyloid oligomers and cellular prion protein in Alzheimerâ€™s disease. Journal of Molecular Medicine, 2010, 88, 331-338.	1.7	75
155	Intraneuronal Î²-amyloid accumulation and synapse pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2010, 119, 523-541.	3.9	341
156	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after AÎ²42 immunisation in Alzheimerâ€™s disease. Acta Neuropathologica, 2010, 120, 13-20.	3.9	80
157	Neuropathology after active AÎ²42 immunotherapy: implications for Alzheimerâ€™s disease pathogenesis. Acta Neuropathologica, 2010, 120, 369-384.	3.9	122
158	Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathologica, 2010, 120, 277-286.	3.9	244

#	Article	IF	Citations
159	Novel therapeutic approach for Alzheimerâ€™s disease by removing amyloid Î² protein from the brain with an extracorporeal removal system. Journal of Artificial Organs, 2010, 13, 31-37.	0.4	24
160	Immunotherapeutic approaches for Alzheimerâ€™s disease in transgenic mouse models. Brain Structure and Function, 2010, 214, 201-218.	1.2	36
161	Macrophages in Alzheimerâ€™s disease: the blood-borne identity. Journal of Neural Transmission, 2010, 117, 961-970.	1.4	94
162	Regulation of Î² cleavage of amyloid precursor protein. Neuroscience Bulletin, 2010, 26, 417-427.	1.5	11
163	Amyloid-modifying therapies for Alzheimerâ€™s disease: therapeutic progress and its implications. Age, 2010, 32, 365-384.	3.0	11
164	Alterations of the Sphingolipid Pathway in Alzheimerâ€™s Disease: New Biomarkers and Treatment Targets?. NeuroMolecular Medicine, 2010, 12, 331-340.	1.8	112
165	Humanin and the Receptors for Humanin. Molecular Neurobiology, 2010, 41, 22-28.	1.9	51
166	Why Pleiotropic Interventions are Needed for Alzheimer's Disease. Molecular Neurobiology, 2010, 41, 392-409.	1.9	141
167	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	4.9	3,792
168	Bapineuzumab in Alzheimer's disease: where now?. Lancet Neurology, The, 2010, 9, 134-136.	4.9	11
169	11C-PiB PET assessment of change in fibrillar amyloid-Î² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	4.9	674
170	Alzheimer's disease: clinical trials and drug development. Lancet Neurology, The, 2010, 9, 702-716.	4.9	1,033
171	Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. Journal of Neuroimmunology, 2010, 223, 104-114.	1.1	22
172	Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiology of Disease, 2010, 39, 301-310.	2.1	16
173	The roles of TNF in brain dysfunction and disease. , 2010, 128, 519-548.		190
174	The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends in Genetics, 2010, 26, 84-93.	2.9	122
175	Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse. BMC Neuroscience, 2010, 11, 130.	0.8	158
176	Amyloid Î² and APP as biomarkers for Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 23-29.	1.2	104

#	Article	IF	Citations
177	Galectinâ€3 secreted by human umbilical cord bloodâ€derived mesenchymal stem cells reduces amyloidâ€Î²42 neurotoxicity in vitro. FEBS Letters, 2010, 584, 3601-3608.	1.3	44
178	Basic mechanisms of neurodegeneration: a critical update. Journal of Cellular and Molecular Medicine, 2010, 14, 457-487.	1.6	330
179	Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrP^{Sc}, even upon LPS stimulation. Glia, 2010, 58, 2017-2030.	2.5	88
180	Beyond diagnosis: What biomarkers are teaching us about the â€œbioâ€logy of Alzheimer disease. Annals of Neurology, 2010, 67, 283-285.	2.8	6
181	¹⁸Fâ€flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	2.8	582
182	A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Annals of Neurology, 2010, 68, 521-534.	2.8	685
183	Strategies for the Inhibition of Protein Aggregation in Human Diseases. ChemBioChem, 2010, 11, 1018-1035.	1.3	120
184	Mercury(II) promotes the in vitro aggregation of tau fragment corresponding to the second repeat of microtubuleâ€binding domain: Coordination and conformational transition. Biopolymers, 2010, 93, 1100-1107.	1.2	18
185	Subâ€millimeter isotropic MRI for segmentation of subcortical brain regions and brain visualization. Journal of Magnetic Resonance Imaging, 2010, 31, 980-986.	1.9	7
186	Amyloid Î² accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau doubleâ€transgenic mouse model. Journal of Neuroscience Research, 2010, 88, 3547-3554.	1.3	27
187	An AÎ² concatemer with altered aggregation propensities. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 2025-2035.	1.1	1
188	The biochemical aftermath of anti-amyloid immunotherapy. Molecular Neurodegeneration, 2010, 5, 39.	4.4	38
189	Neuronal growthâ€inhibitory factor (metallothioneinâ€3): structureâ€“function relationships. FEBS Journal, 2010, 277, 2912-2920.	2.2	31
190	Neuronal growthâ€inhibitory factor (metallothioneinâ€3): evaluation of the biological function of growthâ€inhibitory factor in the injured and neurodegenerative brain. FEBS Journal, 2010, 277, 2931-2939.	2.2	36
191	Traumatic brain injury and amyloid-Î² pathology: a link to Alzheimer's disease?. Nature Reviews Neuroscience, 2010, 11, 361-370.	4.9	469
192	Are We Prepared to Deal With the Alzheimer's Disease Pandemic?. Clinical Pharmacology and Therapeutics, 2010, 88, 563-565.	2.3	11
193	DNA primeâ€“protein boost increased the titer, avidity and persistence of anti-AÎ² antibodies in wild-type mice. Gene Therapy, 2010, 17, 261-271.	2.3	39
194	Biomarkers in Alzheimer's disease drug development. Nature Medicine, 2010, 16, 1218-1222.	15.2	118

#	Article	IF	Citations
195	Initiation and propagation of neurodegeneration. Nature Medicine, 2010, 16, 1201-1204.	15.2	40
196	The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nature Medicine, 2010, 16, 1210-1214.	15.2	301
197	Genome-wide association studies: the key to unlocking neurodegeneration?. Nature Neuroscience, 2010, 13, 789-794.	7.1	90
198	Alzheimer's disease: strategies for disease modification. Nature Reviews Drug Discovery, 2010, 9, 387-398.	21.5	928
199	The turn formation at positions 22 and 23 in the 42â€mer amyloid Î² peptide: The emerging role in the pathogenesis of Alzheimer's disease. Geriatrics and Gerontology International, 2010, 10, S169-79.	0.7	19
200	Mary S. Easton Center of Alzheimer's Disease Research at UCLA: Advancing the Therapeutic Imperative. Journal of Alzheimer's Disease, 2010, 19, 375-388.	1.2	2
202	In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through?. International Journal of Alzheimer's Disease, 2010, 2010, 1-11.	1.1	11
203	Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight. Journal of Alzheimer's Disease, 2010, 20, 5-16.	1.2	23
204	Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches. Current Aging Science, 2010, 3, 46-56.	0.4	41
205	Amyloid-β Immunotherapy for Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 197-206.	0.8	80
206	Are Î³-secretase inhibitors detrimental for Alzheimer's disease patients?. Journal of Alzheimer's Disease, 2010, 22, 401-404.	1.2	10
207	Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy, 2010, 2, 347-365.	1.0	10
208	Alzheimer's Disease: A General Introduction and Pathomechanism. Journal of Alzheimer's Disease, 2010, 22, S5-S19.	1.2	143
209	Synergistic Effects of Long-Term Antioxidant Diet and Behavioral Enrichment on Â-Amyloid Load and Non-Amyloidogenic Processing in Aged Canines. Journal of Neuroscience, 2010, 30, 9831-9839.	1.7	55
210	The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology. Reviews in the Neurosciences, 2010, 21, 83-93.	1.4	72
211	The older brain, inflammation, vaccination and the prevention of dementia. Reviews in Clinical Gerontology, 2010, 20, 288-308.	0.5	0
212	Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid Î²-related Behavioral Deficits in a Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2010, 285, 3417-3427.	1.6	36
213	Effects of Synaptic Modulation on Î²-Amyloid, Synaptophysin, and Memory Performance in Alzheimer's Disease Transgenic Mice. Journal of Neuroscience, 2010, 30, 14299-14304.	1.7	125

#	Article	IF	Citations
214	Generation and Therapeutic Efficacy of Highly Oligomer-Specific Î²-Amyloid Antibodies. Journal of Neuroscience, 2010, 30, 10369-10379.	1.7	97
215	Alzheimer's Disease and the Amyloid-Î² Peptide. Journal of Alzheimer's Disease, 2010, 19, 311-323.	1.2	1,270
216	Bapineuzumab: anti-Î²-amyloid monoclonal antibodies for the treatment of Alzheimerâ€™s disease. Immunotherapy, 2010, 2, 767-782.	1.0	52
217	Misframed Proteins and Neurodegeneration: A Novel View on Alzheimerâ€™s and Parkinsonâ€™s Diseases. Neurodegenerative Diseases, 2010, 7, 76-79.	0.8	19
218	Immunomodulation for prion and prion-related diseases. Expert Review of Vaccines, 2010, 9, 1441-1452.	2.0	18
219	Beneficial Catalytic Immunity to AÎ² Peptide. Rejuvenation Research, 2010, 13, 179-187.	0.9	17
220	Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model. Journal of Neuroscience, 2010, 30, 16559-16566.	1.7	254
221	Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin, 2010, 6, 931-935.	2.4	33
222	Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Amyloid β-Induced Memory Impairment and Apoptosis by Inhibiting Neuronal Cell Death. Current Alzheimer Research, 2010, 7, 540-548.	0.7	55
223	Tauâ€tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDPâ€17 tauâ€mutant mice. FASEB Journal, 2010, 24, 2904-2915.	0.2	32
224	Are we getting to grips with Alzheimer's disease at last?. Brain, 2010, 133, 1297-1299.	3.7	7
225	Beneficial effect of human anti-amyloid-Î² active immunization on neurite morphology and tau pathology. Brain, 2010, 133, 1312-1327.	3.7	138
226	Antibody Therapy in Neurodegenerative Disease. Reviews in the Neurosciences, 2010, 21, 273-87.	1.4	21
227	Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid. Current Alzheimer Research, 2010, 7, 40-55.	0.7	109
228	Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD. Current Alzheimer Research, 2010, 7, 280-286.	0.7	68
229	Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. Physiological Reviews, 2010, 90, 465-494.	13.1	389
230	Simplified Î²-amyloid peptides for safer Alzheimerâ€™s vaccines development. Hum Vaccin, 2010, 6, 936-947.	2.4	2
231	Are AÎ² and Its Derivatives Causative Agents or Innocent Bystanders in AD?. Neurodegenerative Diseases, 2010, 7, 32-37.	0.8	33

#	Article	IF	Citations
232	AFFITOMEÂ® technology in neurodegenerative diseases: The doubling advantage. Hum Vaccin, 2010, 6, 948-952.	2.4	45
233	Virus-like particle based vaccines for Alzheimer disease. Hum Vaccin, 2010, 6, 926-930.	2.4	27
234	TAU Aggregation is a Therapeutic Target for Alzheimers Disease. Current Alzheimer Research, 2010, 7, 665-669.	0.7	44
235	Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. Brain, 2010, 133, 3685-3698.	3.7	94
236	The Alzheimer's Disease Mitochondrial Cascade Hypothesis. Journal of Alzheimer's Disease, 2010, 20, S265-S279.	1.2	435
237	Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. Neurosurgery Clinics of North America, 2010, 21, 95-109.	0.8	21
238	The Vascular Hypothesis of Alzheimerâ€™s Disease: Bench to Bedside and Beyond. Neurodegenerative Diseases, 2010, 7, 116-121.	0.8	142
240	Rapid Cerebral Amyloid Binding by AÎ² Antibodies Infused into Î²-Amyloid Precursor Protein Transgenic Mice. Biological Psychiatry, 2010, 68, 971-974.	0.7	14
241	Microglia in neurodegenerative disease. Nature Reviews Neurology, 2010, 6, 193-201.	4.9	1,354
242	Intravenous Immunoglobulins as a Treatment for AlzheimerÊ¼s Disease. Drugs, 2010, 70, 513-528.	4.9	101
243	Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Annals of the New York Academy of Sciences, 2010, 1207, 58-70.	1.8	56
244	The Mitochondrial Secret(ase) of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, S381-S400.	1.2	28
245	Monoclonal Antibody Against the Turn of the 42-Residue Amyloid Î²-Protein at Positions 22 and 23. ACS Chemical Neuroscience, 2010, 1, 747-756.	1.7	51
246	Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2010, 285, 36958-36968.	1.6	170
247	Can Alzheimer disease be prevented by amyloid-Î² immunotherapy?. Nature Reviews Neurology, 2010, 6, 108-119.	4.9	329
248	Back to the Plaque. Annual Reports in Medicinal Chemistry, 2010, 45, 314-328.	0.5	0
249	Genetic Factors in Alzheimer Disease and Dementia. , 2010, , 681-697.		0
250	Antibody concentrations to AÎ²1â€“42 monomer and soluble oligomers in untreated and antibodyâ€“antigen-dissociated intravenous immunoglobulin preparations. International Immunopharmacology, 2010, 10, 115-119.	1.7	46

#	Article	IF	Citations
251	Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 847-859.	1.8	71
252	Activation of mixed glia by AÎ²-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain, Behavior, and Immunity, 2010, 24, 598-607.	2.0	70
253	Intramuscular delivery of a single chain antibody gene prevents brain AÎ² deposition and cognitive impairment in a mouse model of Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2010, 24, 1281-1293.	2.0	35
254	Reduction of amyloid Î²-peptide accumulation in Tg2576 transgenic mice by oral vaccination. Biochemical and Biophysical Research Communications, 2010, 399, 593-599.	1.0	20
255	Tau protein and tau aggregation inhibitors. Neuropharmacology, 2010, 59, 276-289.	2.0	162
256	Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience, 2010, 169, 516-531.	1.1	117
257	Valproic acid enhances microglial phagocytosis of amyloid-Î²1â€“42. Neuroscience, 2010, 169, 505-515.	1.1	49
258	â€˜Too much good newsâ€™ â€“ are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?. Trends in Neurosciences, 2010, 33, 381-389.	4.2	170
259	Analysis of three plasmid systems for use in DNA AÎ²42 immunization as therapy for Alzheimer's disease. Vaccine, 2010, 28, 5280-5287.	1.7	30
260	Brain Atrophy in Healthy Aging Is Related to CSF Levels of AÎ²1-42. Cerebral Cortex, 2010, 20, 2069-2079.	1.6	102
261	REVIEW: Î³â€Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	1.9	63
262	Individual Prediction of Cognitive Decline in Mild Cognitive Impairment Using Support Vector Machine-Based Analysis of Diffusion Tensor Imaging Data. Journal of Alzheimer's Disease, 2010, 22, 315-327.	1.2	111
263	Targeting AÎ² and tau in Alzheimer's disease, an early interim report. Experimental Neurology, 2010, 223, 252-266.	2.0	80
264	Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Experimental Neurology, 2010, 224, 472-485.	2.0	162
265	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 2010, 6, 202.	0.4	443
266	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology Core. Alzheimer's and Dementia, 2010, 6, 274-279.	0.4	31
267	Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimer's and Dementia, 2010, 6, 420-424.	0.4	186
268	Memantine. American Journal of Pathology, 2010, 176, 540-541.	1.9	4

#	Article	IF	Citations
269	Pro: Can neuropathology really confirm the exact diagnosis?. Alzheimer's Research and Therapy, 2010, 2, 10.	3.0	4
270	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research and Therapy, 2010, 2, 1.	3.0	189
271	Reduction of Brain Î²-Amyloid (AÎ²) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and AÎ² Clearance. Journal of Biological Chemistry, 2010, 285, 22091-22102.	1.6	95
272	Bapineuzumab. Expert Opinion on Biological Therapy, 2010, 10, 1121-1130.	1.4	81
273	Low Concentrations of Anti-AÎ² Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology. Human Gene Therapy, 2010, 21, 1569-1576.	1.4	8
274	Monoclonal antibodies against Î²-amyloid (AÎ²) for the treatment of Alzheimer's disease: the AÎ² target at a crossroads. Expert Opinion on Biological Therapy, 2011, 11, 679-686.	1.4	40
275	Soluble amyloid Î²-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5819-5824.	3.3	770
276	Investigational drugs for the treatment of AD: what can we learn from negative trials?. Alzheimer's Research and Therapy, 2011, 3, 14.	3.0	5
277	Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease. Alzheimer's Research and Therapy, 2011, 3, 21.	3.0	17
278	Antibody-based therapy in Alzheimer's disease. Expert Opinion on Biological Therapy, 2011, 11, 343-357.	1.4	56
279	A multimeric immunogen for the induction of immune memory to betaâ€amyloid. Immunology and Cell Biology, 2011, 89, 604-609.	1.0	17
280	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. World Journal of Biological Psychiatry, 2011, 12, 2-32.	1.3	77
281	Alzheimerâ€™s Disease: Future Treatments. Journal of the American Medical Directors Association, 2011, 12, 1-7.	1.2	31
282	Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ÃŸ-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas. Biological Psychiatry, 2011, 70, 183-190.	0.7	93
283	Assessing the contribution of inflammation in models of Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 886-890.	1.6	102
284	CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques. Alzheimer's Research and Therapy, 2011, 3, 12.	3.0	27
285	Therapeutic intervention for Alzheimer's disease with Î³-secretase inhibitors: still a viable option?. Expert Opinion on Investigational Drugs, 2011, 20, 325-341.	1.9	86
286	Amyloid Precursor Protein Processing and Alzheimer's Disease. Annual Review of Neuroscience, 2011, 34, 185-204.	5.0	1,455

#	Article	IF	Citations
287	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. Molecular Diagnosis and Therapy, 2011, 15, 83-102.	1.6	25
288	Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI. NeuroImage, 2011, 58, 579-587.	2.1	131
289	Endothelin receptor antagonists: Potential in Alzheimer's disease. Pharmacological Research, 2011, 63, 525-531.	3.1	40
290	Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage, 2011, 54, S204-S217.	2.1	543
291	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery, 2011, 10, 698-712.	21.5	1,766
292	Current and Emerging Drug Treatment Options for AlzheimerÊ¼s Disease. Drugs, 2011, 71, 2031-2065.	4.9	196
293	Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. Molecular Neurodegeneration, 2011, 6, 20.	4.4	32
294	Amyloid Clearance as a Treatment Target Against Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 61-73.	1.2	67
295	Molecular Dynamics Simulations of Low-Ordered Alzheimer Î²-Amyloid Oligomers from Dimer to Hexamer on Self-Assembled Monolayers. Langmuir, 2011, 27, 14876-14887.	1.6	57
296	Fulvic Acid Inhibits Aggregation and Promotes Disassembly of Tau Fibrils Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 143-153.	1.2	70
297	Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine, 2011, 17, 1060-1065.	15.2	434
298	Amyloid imaging for Alzheimer's disease. Expert Opinion on Medical Diagnostics, 2011, 5, 527-538.	1.6	2
299	Clinical Neuroimmunology. , 2011, , .		0
300	Solanezumab for Alzheimer's disease. Expert Opinion on Biological Therapy, 2011, 11, 787-798.	1.4	39
301	Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimer's Research and Therapy, 2011, 3, 5.	3.0	22
302	The Mitochondria-Targeted Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 15703-15715.	1.7	354
303	The role of Î²-amyloid peptide in neurodegenerative diseases. Ageing Research Reviews, 2011, 10, 440-452.	5.0	49
304	Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2011, 25, 997-1019.	2.0	160

#	Article	IF	Citations
305	Dental X-ray exposure and Alzheimerâ€™s disease: A hypothetical etiological association. Medical Hypotheses, 2011, 77, 29-34.	0.8	2
306	Intranasal inoculation with an adenovirus vaccine encoding ten repeats of AÎ²3â€“10 induces Th2 immune response against amyloid-Î² in wild-type mouse. Neuroscience Letters, 2011, 505, 128-133.	1.0	5
307	Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. Neuroscience Research, 2011, 70, 339-348.	1.0	154
308	Animal Models of Neurodegenerative Diseases. Advances in Neurobiology, 2011, , 49-101.	1.3	0
309	Effect of rice-expressed amyloid Î² in the Tg2576 Alzheimer's disease transgenic mouse model. Vaccine, 2011, 29, 6252-6258.	1.7	18
310	Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying AÎ²1â€“43/IL-10 cDNA. Vaccine, 2011, 29, 7474-7482.	1.7	10
311	Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends in Pharmacological Sciences, 2011, 32, 141-147.	4.0	117
312	Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimerâ€™s disease pathology. Progress in Lipid Research, 2011, 50, 313-330.	5.3	172
313	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	2.8	119
314	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Progress in Neurobiology, 2011, 95, 547-556.	2.8	30
315	Biomarkers and evolution in Alzheimer disease. Progress in Neurobiology, 2011, 95, 510-513.	2.8	33
316	Autoimmune and inflammatory mechanisms of CNS damage. Progress in Neurobiology, 2011, 95, 301-333.	2.8	62
317	The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology, 2011, 95, 718-728.	2.8	190
318	Novel insights for the treatment of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 373-379.	2.5	82
319	Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiology of Aging, 2011, 32, 31-41.	1.5	172
320	Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiology of Aging, 2011, 32, 1341-1371.	1.5	454
321	Aging and excitotoxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice. Neurobiology of Aging, 2011, 32, 2320.e1-2320.e9.	1.5	18
322	Mechanisms of AD neurodegeneration may be independent of AÎ² and its derivatives. Neurobiology of Aging, 2011, 32, 372-379.	1.5	73

#	Article	IF	Citations
323	Current perspectives on pharmacotherapy of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2011, 12, 335-350.	0.9	62
324	Report of the task force on designing clinical trials in early (predementia) AD. Neurology, 2011, 76, 280-286.	1.5	157
325	Alzheimer's disease. Lancet, The, 2011, 377, 1019-1031.	6.3	2,051
326	Transgenic Rice Expressing Amyloid Î²-peptide for Oral Immunization. International Journal of Biological Sciences, 2011, 7, 301-307.	2.6	24
327	When Will Alzheimer's Disease be Cured? A Pharmaceutical Perspective. Journal of Alzheimer's Disease, 2011, 24, 43-52.	1.2	17
328	Feasibility of Predicting MCI/AD Using Neuropsychological Tests and SerumÎ²-Amyloid. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	5
329	Passive (Amyloid-Î²) Immunotherapy Attenuates Monoaminergic Axonal Degeneration in the AÎ²PPswe/PS1dE9 Mice. Journal of Alzheimer's Disease, 2011, 23, 271-279.	1.2	16
330	Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	4
332	Alzheimer's disease is TH17 related autoimmune disease against misfoded beta amyloid. Nature Precedings, 2011, , .	0.1	0
333	Alzheimer's disease is TH17 related autoimmune disease against misfolded beta amyloid. Nature Precedings, 2011, , .	0.1	1
334	Protein Regge Trajectories, Phase Coexistence and Loop Aetiology in Alzheimers Disease. Nature Precedings, 2011, , .	0.1	0
335	Neurodegeneration: Potential Causes, Prevention, and Future Treatment Options. Nature Precedings, 0, , .	0.1	0
336	Alzheimer's disease is TH17 related autoimmune disease against misfolded beta amyloid. Nature Precedings, 2011, , .	0.1	2
337	Effect of Neocortical and Hippocampal Amyloid Deposition upon Galaninergic and Cholinergic Neurites in AÎ²PPswe/PS1Î”E9 Mice. Journal of Alzheimer's Disease, 2011, 25, 491-504.	1.2	19
338	TNF and Leptin Tell Essentially the Same Story in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 201-205.	1.2	46
339	Ageing and health. , 0, , 87-125.		1
340	Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins. Journal of Central Nervous System Disease, 2011, 3, JCNSD.S5018.	0.7	9
341	Future Targeted Disease Modifying Drugs for Alzheimer's Disease. Recent Patents on CNS Drug Discovery, 2011, 6, 65-76.	0.9	1

#	Article	IF	Citations
342	Alzheimerâ€™s disease vaccines: promises and pitfalls. Clinical Investigation, 2011, 1, 969-988.	0.0	2
343	Clinical issues in old age â€•the challenges of geriatric medicine. Quality in Ageing and Older Adults, 2011, 12, 44-49.	0.4	3
344	γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes. Current Topics in Medicinal Chemistry, 2011, 11, 1555-1570.	1.0	168
345	Determination of Spatial and Temporal Distribution of Microglia by 230nm-High-Resolution, High-Throughput Automated Analysis Reveals Different Amyloid Plaque Populations in an APP/PS1 Mouse Model of Alzheimers Disease. Current Alzheimer Research, 2011, 8, 781-788.	0.7	30
346	Pharmacological Treatment of Alzheimer Disease. Canadian Journal of Psychiatry, 2011, 56, 579-588.	0.9	96
347	Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials. Current Pharmaceutical Design, 2011, 17, 3434-3445.	0.9	20
348	Tau as a Therapeutic Target for Alzheimers Disease. Current Alzheimer Research, 2011, 8, 666-677.	0.7	65
349	A Clinical Perspective: Anti Taus Treatment in Alzheimers Disease. Current Alzheimer Research, 2011, 8, 686-688.	0.7	10
350	Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide. Current Protein and Peptide Science, 2011, 12, 235-257.	0.7	20
351	AÎ²-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2011, 70, 944-959.	0.9	228
352	Current conceptions of the etiology and risk factors for Alzheimerâ€™s disease and their possible implications on the design of dementia clinical trials. Clinical Investigation, 2011, 1, 1491-1503.	0.0	0
353	The Impacts of Hg(II) Tightly Binding on the Alzheimerâ€™s Tau Construct R3: Misfolding and Aggregation. Bulletin of the Chemical Society of Japan, 2011, 84, 1362-1367.	2.0	5
354	The Î³-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	1.2	53
355	Is TNF a Link between Aging-Related Reproductive Endocrine Dyscrasia and Alzheimer's Disease?. Journal of Alzheimer's Disease, 2011, 27, 691-699.	1.2	15
356	Humanin Signal for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 27-32.	1.2	13
357	Biochemical and Morphological Characterization of the AÎ²PP/PS/Tau Triple Transgenic Mouse Model and Its Relevance to Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 361-376.	1.2	18
358	Ultra-High Field 7T MRI: A New Tool for Studying Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 91-95.	1.2	39
359	Dendritic Cells Regulate Amyloid-Î²-Specific T-Cell Entry into the Brain: The Role of Perivascular Amyloid-Î². Journal of Alzheimer's Disease, 2011, 27, 99-111.	1.2	25

#	Article	IF	Citations
360	Addressing the complex etiology of Alzheimerâ€™s disease: the role of p25/Cdk5. Future Neurology, 2011, 6, 481-496.	0.9	3
361	Microglial alterations in human Alzheimer's disease following AÎ²42 immunization. Neuropathology and Applied Neurobiology, 2011, 37, 513-524.	1.8	88
362	Immunotherapy for Alzheimerâ€™s disease. Journal of Internal Medicine, 2011, 269, 54-63.	2.7	167
363	Passive immunization targeting pathological phosphoâ€tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. Journal of Neurochemistry, 2011, 118, 658-667.	2.1	271
364	The World of Dementia Beyond 2020. Journal of the American Geriatrics Society, 2011, 59, 923-927.	1.3	73
365	Antiâ€amyloid precursor protein immunoglobulins inhibit amyloidâ€Î² production by steric hindrance. FEBS Journal, 2011, 278, 167-178.	2.2	8
366	Recent advances in drug treatment for <scp>A</scp>lzheimer's dementia. Asia-Pacific Psychiatry, 2011, 3, 115-119.	1.2	1
367	Therapeutic applications of antibodies in non-infectious neurodegenerative diseases. New Biotechnology, 2011, 28, 511-517.	2.4	7
368	Many are called, yet few are chosen. Are neuropsychiatric clinical trials letting us down?. Drug Discovery Today, 2011, 16, 173-175.	3.2	9
369	Estrogen-induced signaling attenuates soluble AÎ² peptide-mediated dysfunction of pathways in synaptic plasticity. Brain Research, 2011, 1383, 1-12.	1.1	22
370	Elimination of Amyloid Î² from the Brain, its Failure in Alzheimer's Disease and Implications for Therapy. , 2011, , 97-101.		5
371	Disease-modifying treatments for Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2011, 4, 203-216.	1.5	110
372	Alzheimerâ€™s Disease: The Challenge of the Second Century. Science Translational Medicine, 2011, 3, 77sr1.	5.8	1,109
373	Alzheimerâ€™s disease is not â€œbrain agingâ€: neuropathological, genetic, and epidemiological human studies. Acta Neuropathologica, 2011, 121, 571-587.	3.9	273
374	Stages of granulovacuolar degeneration: their relation to Alzheimerâ€™s disease and chronic stress response. Acta Neuropathologica, 2011, 122, 577-589.	3.9	95
375	Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimerâ€™s disease. Journal of Neural Transmission, 2011, 118, 747-752.	1.4	96
376	APP Transgenic Mice: Their Use and Limitations. NeuroMolecular Medicine, 2011, 13, 117-137.	1.8	69
377	Immunotherapy for Tauopathies. Journal of Molecular Neuroscience, 2011, 45, 690-695.	1.1	33

#	Article	IF	Citations
378	Aberrant protein structure and diseases of the brain. Irish Journal of Medical Science, 2011, 180, 15-22.	0.8	9
379	The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. Journal of Translational Medicine, 2011, 9, 127.	1.8	14
380	T cell mediated cerebral hemorrhages and microhemorrhages during passive AÎ² immunization in APPPS1 transgenic mice. Molecular Neurodegeneration, 2011, 6, 22.	4.4	14
381	Combined Effects of Hematopoietic Progenitor Cell Mobilization from Bone Marrow by Granulocyte Colony Stimulating Factor and AMD3100 and Chemotaxis into the Brain Using Stromal Cellâ€Derived Factorâ€1Î± in an Alzheimer's Disease Mouse Model. Stem Cells, 2011, 29, 1075-1089.	1.4	50
382	Factors responsible for neurofibrillary tangles and neuronal cell losses in tauopathy. Journal of Neuroscience Research, 2011, 89, 576-584.	1.3	15
383	Apomorphine treatment in Alzheimer mice promoting amyloidâ€Î² degradation. Annals of Neurology, 2011, 69, 248-256.	2.8	134
384	Amyloidâ€Î² associated volume loss occurs only in the presence of phosphoâ€tau. Annals of Neurology, 2011, 70, 657-661.	2.8	109
385	Amyloidâ€beta plaque growth in cognitively normal adults: Longitudinal [¹¹C]Pittsburgh compound B data. Annals of Neurology, 2011, 70, 857-861.	2.8	131
386	Microglia in the CNS: Immigrants from another world. Glia, 2011, 59, 177-187.	2.5	203
387	Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches. CNS and Neurological Disorders - Drug Targets, 2011, 10, 163-174.	0.8	33
388	Therapeutic potential of vaccines for Alzheimerâ€™s disease. Immunotherapy, 2011, 3, 287-298.	1.0	15
389	Stem Cell Therapy for Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 459-485.	0.8	43
390	Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	0.7	51
391	Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation. Current Medicinal Chemistry, 2011, 18, 5430-5447.	1.2	26
392	Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease. Current Alzheimer Research, 2011, 8, 67-80.	0.7	247
393	Therapeutic Interventions Targeting Beta Amyloid Pathogenesis in an Aging Dog Model. Current Neuropharmacology, 2011, 9, 651-661.	1.4	17
394	Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies. Current Alzheimer Research, 2011, 8, 659-665.	0.7	68
395	Pharmacological Approaches of Alzheimer's Disease: An Update. Current Drug Therapy, 2011, 6, 186-196.	0.2	0

#	Article	IF	Citations
396	Three Postulates to Help Identify the Cause of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 657-668.	1.2	31
397	Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. Archives of Neurology, 2011, 68, 1062.	4.9	173
398	Î³-secretase inhibitors for treating Alzheimerâ€™s disease: rationale and clinical data. Clinical Investigation, 2011, 1, 1175-1194.	0.0	2
399	Evodiamine improves congnitive abilities in SAMP8 and APPswe/PS1Î”E9 transgenic mouse models of Alzheimer's disease. Acta Pharmacologica Sinica, 2011, 32, 295-302.	2.8	72
400	Naturally Occurring Autoantibodies against Î²-Amyloid: Investigating Their Role in Transgenic Animal andIn VitroModels of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 5847-5854.	1.7	111
401	Pittsburgh Compound B-Negative Dementiaâ€”A Possibility of Misdiagnosis of Patients With Non-Alzheimer Disease-Type Dementia as Having AD. Journal of Geriatric Psychiatry and Neurology, 2011, 24, 123-126.	1.2	18
402	Mapping Out Biomarkers for Alzheimer Disease. JAMA - Journal of the American Medical Association, 2011, 305, 304.	3.8	24
403	The Second-Generation Active AÂ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects. Journal of Neuroscience, 2011, 31, 9323-9331.	1.7	167
404	Treat Alzheimer Disease Before It Is Symptomatic. Archives of Neurology, 2011, 68, 1237.	4.9	7
405	Alzheimers Disease: Pathological Mechanisms and Recent Insights. Current Neuropharmacology, 2011, 9, 674-684.	1.4	46
406	Glaucoma and Alzheimerâ€™s disease in the elderly. Aging Health, 2011, 7, 719-733.	0.3	12
407	Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-Î² Immunotherapy. Journal of Neuroscience, 2011, 31, 4124-4136.	1.7	97
408	Is targeting beta-amyloid pathology, with immunotherapy, an effective treatment option for Alzheimer's disease?. Reviews in Clinical Gerontology, 2011, 21, 340-345.	0.5	1
409	Marketplace of Memory: What the Brain Fitness Technology Industry Says About Us and How We Can Do Better. Gerontologist, The, 2011, 51, 590-596.	2.3	45
410	Serotonin signaling is associated with lower amyloid-Î² levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14968-14973.	3.3	281
411	MHC-Independent Genetic Factors Control the Magnitude of CD4+ T Cell Responses to Amyloid-Î² Peptide in Mice through Regulatory T Cell-Mediated Inhibition. Journal of Immunology, 2011, 187, 4492-4500.	0.4	19
412	A Systematic Review of Single Chinese Herbs for Alzheimer's Disease Treatment. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	0.5	32
413	Fiber Tracts Anomalies in APPxPS1 Transgenic Mice Modeling Alzheimer's Disease. Journal of Aging Research, 2011, 2011, 1-12.	0.4	10

#	Article	IF	Citations
414	New Tools for the Study of Alzheimerâ€™s Disease. Neuroscientist, 2011, 17, 592-605.	2.6	12
415	What is the pathological significance of tau oligomers?. Biochemical Society Transactions, 2012, 40, 693-697.	1.6	49
416	How the Interval between Prime and Boost Injection Affects the Immune Response in a Computational Model of the Immune System. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-9.	0.7	131
417	Postmortem findings in a patient with cerebral amyloid angiopathy actively treated with corticosteroid. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 47-52.	1.4	11
418	Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease. Current Alzheimer Research, 2012, 9, 99-109.	0.7	32
419	Role of Formyl Peptide Receptors (FPR) in Abnormal Inflammation Responses Involved in Neurodegenerative Diseases. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2012, 11, 20-36.	1.1	19
420	Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews, 2012, 64, 1004-1026.	7.1	65
421	Beyond Amyloid. Advances in Pharmacology, 2012, 64, 213-271.	1.2	32
422	Alzheimerâ€™s Disease in the Retina: Imaging Retinal AÎ² Plaques for Early Diagnosis and Therapy Assessment. Neurodegenerative Diseases, 2012, 10, 285-293.	0.8	184
423	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	1.0	121
424	Treatment Strategies Targeting Amyloid Â-Protein. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006387-a006387.	2.9	96
425	Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 329-335.	0.9	47
426	Could immunomodulation be used to prevent prion diseases?. Expert Review of Anti-Infective Therapy, 2012, 10, 307-317.	2.0	13
427	Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacology, 2012, 37, 261-277.	2.8	43
429	Alzheimer's Disease, Cerebrovascular Disease, and the Î²-amyloid Cascade. Canadian Journal of Neurological Sciences, 2012, 39, 712-728.	0.3	141
430	An Exploratory Analysis of Pharmaceutical Drugs as Basic Research Tools. Drug Information Journal, 2012, 46, 192-196.	0.5	1
431	Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial AlzheimerÂ's Disease Mutation Carriers. Dementia and Geriatric Cognitive Disorders Extra, 2012, 2, 652-657.	0.6	9
432	Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions. Current Pharmaceutical Design, 2012, 18, 1131-1147.	0.9	146

#	Article	IF	Citations
433	Novel Disease-Modifying Therapies for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 475-492.	1.2	78
434	Progress in diagnosis and management of Alzheimer's disease. Quality in Ageing and Older Adults, 2012, 13, 189-196.	0.4	0
435	Inhibition of polyglutamine-mediated proteotoxicity by Astragalus membranaceus polysaccharide through the DAF-16/FOXO transcription factor in Caenorhabditis elegans. Biochemical Journal, 2012, 441, 417-424.	1.7	78
436	Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease. The Cochrane Library, 0, , .	1.5	0
437	Cerebral blood flow in Alzheimer’s disease. Vascular Health and Risk Management, 2012, 8, 599.	1.0	162
438	Translational Research in Neurology. Archives of Neurology, 2012, 69, 969-77.	4.9	13
441	Genomic and Nongenomic Signaling Induced by 1Î±,25(OH)2-Vitamin D3 Promotes the Recovery of Amyloid-Î² Phagocytosis by Alzheimer's Disease Macrophages. Journal of Alzheimer's Disease, 2012, 29, 51-62.	1.2	107
442	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
443	Cerebrospinal Fluid AÎ² and Tau Level Fluctuation in an Older Clinical Cohort. Archives of Neurology, 2012, 69, 246.	4.9	45
444	MOCA is an integrator of the neuronal death signals that are activated by familial Alzheimer's disease-related mutants of amyloid Î² precursor protein and presenilins. Biochemical Journal, 2012, 442, 413-422.	1.7	20
445	Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials. Canadian Journal of Neurological Sciences, 2012, 39, 592-599.	0.3	28
446	Restoring Memory Deficits in Cognitive Diseases. , 2012, , 381-396.		0
447	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. Future Neurology, 2012, 7, 395-401.	0.9	1
448	Drug Treatments in Development for Alzheimer's Disease. Journal of Pharmacy Practice and Research, 2012, 42, 58-65.	0.5	7
449	Internal Medicine, 2012, 101, 113a-113a.	0.0	0
450	Antibody-Aided Clearance of Extracellular Î±-Synuclein Prevents Cell-to-Cell Aggregate Transmission. Journal of Neuroscience, 2012, 32, 13454-13469.	1.7	290
451	Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 2012, 11, 833-846.	21.5	239
452	Inflammatory events at bloodâ€“brain barrier in neuroinflammatory and neurodegenerative disorders: Implications for clinical disease. Epilepsia, 2012, 53, 45-52.	2.6	97

#	Article	IF	Citations
453	Alzheimerâ€™s Disease. Sub-Cellular Biochemistry, 2012, 65, 329-352.	1.0	260
454	Increased Cerebral Metabolism After 1 Year of Deep Brain Stimulation in Alzheimer Disease. Archives of Neurology, 2012, 69, 1141-8.	4.9	148
455	Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications. CNS Neuroscience and Therapeutics, 2012, 18, 64-76.	1.9	32
456	Safety, tolerability, and antibody response of active AÎ² immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurology, The, 2012, 11, 597-604.	4.9	261
460	Tau as a therapeutic target in neurodegenerative disease. , 2012, 136, 8-22.		101
461	Family History and APOE-4 Genetic Risk in Alzheimerâ€™s Disease. Neuropsychology Review, 2012, 22, 298-309.	2.5	51
462	Central angiotensin IIâ€induced Alzheimerâ€like tau phosphorylation in normal rat brains. FEBS Letters, 2012, 586, 3737-3745.	1.3	87
463	Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?. , 2012, 8, 574-583.		28
464	Lâ€™immunothÃ©rapie dans la maladie dâ€™AlzheimerÂ: le point en 2012. NPG Neurologie - Psychiatrie - Geriatrie, 2012, 12, 99-102.	0.1	0
465	Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications. Alzheimer's Research and Therapy, 2012, 4, 20.	3.0	7
466	Brain aging and late-onset Alzheimer's disease: many open questions. International Psychogeriatrics, 2012, 24, S3-S9.	0.6	22
467	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. Journal of Alzheimer's Disease, 2012, 33, S405-S416.	1.2	73
468	Gantenerumab: A Novel Human Anti-AÎ² Antibody Demonstrates Sustained Cerebral Amyloid-Î² Binding and Elicits Cell-Mediated Removal of Human Amyloid-Î². Journal of Alzheimer's Disease, 2012, 28, 49-69.	1.2	335
469	Demyelination of superficial white matter in early Alzheimer's disease: a magnetization transfer imaging study. Neurobiology of Aging, 2012, 33, 428.e7-428.e19.	1.5	55
470	Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiology of Aging, 2012, 33, 2237-2246.	1.5	30
471	DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid Î²-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine, 2012, 30, 1650-1658.	1.7	20
472	Amyloid-Î² Peptide: Dr. Jekyll or Mr. Hyde?. Journal of Alzheimer's Disease, 2012, 33, S111-S120.	1.2	91
473	Monoclonal Antibody Therapy For Malignant Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 121-141.	0.8	20

#	Article	IF	Citations
474	Immunology meets neuroscience â€“ Opportunities for immune intervention in neurodegenerative diseases. Brain, Behavior, and Immunity, 2012, 26, 1-10.	2.0	31
475	Alzheimerâ€™s disease markers from structural MRI and FDG-PET brain images. European Physical Journal Plus, 2012, 127, 1.	1.2	15
476	Current advances in the treatment of Alzheimer's disease: focused on considerations targeting AÎ² and tau. Translational Neurodegeneration, 2012, 1, 21.	3.6	74
477	Alzheimerâ€™s disease: biological aspects, therapeutic perspectives and diagnostic tools. Journal of Physics Condensed Matter, 2012, 24, 244102.	0.7	51
478	Active DNA AÎ²42 vaccination as immunotherapy for Alzheimer disease. Translational Neuroscience, 2012, 3, 307-313.	0.7	20
479	Multiple Sclerosis, Alzheimerâ€™s Disease, and Inflammation: A Hypothetical View. Molecular and Integrative Toxicology, 2012, , 215-252.	0.5	0
480	Solanezumab for the treatment of mild-to-moderate Alzheimerâ€™s disease. Expert Review of Clinical Immunology, 2012, 8, 135-149.	1.3	79
481	Certain new aspects of etiology and pathogenesis of Alzheimerâ€™s disease. Advances in Alzheimer's Disease, 2012, 01, 68-76.	0.3	4
482	Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology toÂTreatment Target. Journal of Experimental and Clinical Medicine, 2012, 4, 135-139.	0.2	7
483	Intranasal inoculation with an adenovirus vaccine encoding ten repeats of AÎ²3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice. Journal of Neuroimmunology, 2012, 249, 16-26.	1.1	15
484	Immunization with a new DNA vaccine for Alzheimer's disease elicited Th2 immune response in BALB/c mice by in vivo electroporation. Journal of the Neurological Sciences, 2012, 313, 17-21.	0.3	12
485	Critical role of intraneuronal AÎ² in Alzheimer's disease: Technical challenges in studying intracellular AÎ². Life Sciences, 2012, 91, 1153-1158.	2.0	36
486	New and emerging treatments for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2012, 12, 535-543.	1.4	50
487	Immunotherapy for Alzheimer diseaseâ€”the challenge of adverse effects. Nature Reviews Neurology, 2012, 8, 465-469.	4.9	107
488	Mitochondrial Abnormalities in Alzheimerâ€™s Disease. Advances in Pharmacology, 2012, 64, 83-126.	1.2	66
489	Nerve Growth Factor and Alzheimer's Disease: New Facts for an Old Hypothesis. Molecular Neurobiology, 2012, 46, 588-604.	1.9	87
490	Epigenetics, Brain and Behavior. Research and Perspectives in Neurosciences, 2012, , .	0.4	5
491	Immunotoxicity, Immune Dysfunction, and Chronic Disease. Molecular and Integrative Toxicology, 2012, , .	0.5	4

#	Article	IF	Citations
492	Overview of Mouse Models for Psychiatric and Neurologic Disorders. , 2012, , 738-751.		0
493	Activation of Protein Kinase C Isozymes for the Treatment of Dementias. Advances in Pharmacology, 2012, 64, 273-302.	1.2	29
495	Practical Lessons from Amyloid Immunotherapy Trials in Alzheimer Disease. Current Alzheimer Research, 2012, 9, 1126-1134.	0.7	5
496	Microglia in Alzheimer's Disease: It's All About Context. International Journal of Alzheimer's Disease, 2012, 2012, 1-11.	1.1	70
497	A Changing Perspective on the Role of Neuroinflammation in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-7.	1.1	37
498	A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines. Scientific World Journal, The, 2012, 2012, 1-15.	0.8	626
499	Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-14.	1.1	66
500	GSK-3Î² and memory formation. Frontiers in Molecular Neuroscience, 2012, 5, 47.	1.4	32
501	Amyloid-Î² Protein Precursor Regulates Phosphorylation and Cellular Compartmentalization of Microtubule Associated Protein Tau. Journal of Alzheimer's Disease, 2012, 29, 211-227.	1.2	19
502	Imaging the Onset and Progression of Alzheimer's Disease: Implications for Prevention Trials. Journal of Alzheimer's Disease, 2012, 33, S305-S312.	1.2	5
503	Historical perspectives on the discovery and development of drugs to treat neurological disorders. , 0, , 129-148.		5
505	4.5 Literatur. , 2012, , .		0
506	Sevoflurane Anesthesia Does Not Impair Acquisition Learning or Memory in the Morris Water Maze in Young Adult and Aged Rats. Anesthesiology, 2012, 117, 1091-1101.	1.3	70
507	Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play. Radiology, 2012, 263, 344-361.	3.6	192
508	Amyloid-Î²â€“Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau. Archives of Neurology, 2012, 69, 709-13.	4.9	122
509	The Amyloid Beta Peptide: A Chemistâ€™s Perspective. Role in Alzheimerâ€™s and Fibrillization. Chemical Reviews, 2012, 112, 5147-5192.	23.0	785
510	Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Human Brain Mapping, 2012, 33, 2586-2602.	1.9	83
511	Cognitive Function in Health and Disease: The Role of Epigenetic Mechanisms. Neurodegenerative Diseases, 2012, 10, 191-194.	0.8	8

#	Article	IF	Citations
512	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British Journal of Clinical Pharmacology, 2012, 73, 504-517.	1.1	253
513	New and emerging treatments for Alzheimer's disease. Expert Opinion on Emerging Drugs, 2012, 17, 147-156.	1.0	25
514	The Classification of Microglial Activation Phenotypes on Neurodegeneration and Regeneration in Alzheimerâ€™s Disease Brain. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 251-266.	1.0	323
515	In Vivo Electroporation of a New Gene Vaccine Encoding Ten Repeats of AÎ²3-10 Prevents Brain AÎ² Deposition and Delays Cognitive Impairment in Young Tg-APPswe/PSEN1dE9 Mice. Neurochemical Research, 2012, 37, 1534-1544.	1.6	11
517	Twenty years of Alzheimerâ€™s diseaseâ€causing mutations. Journal of Neurochemistry, 2012, 120, 3-8.	2.1	123
518	Autoreactiveâ€AÎ² antibodies promote APP Î²â€secretase processing. Journal of Neurochemistry, 2012, 120, 732-740.	2.1	25
519	Tauâ€targeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology, 2012, 165, 1246-1259.	2.7	114
520	Ginkgo biloba extract EGb 761Â® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240Âmg. Journal of Psychiatric Research, 2012, 46, 716-723.	1.5	155
521	Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. , 2012, 134, 8-25.		180
522	Longâ€term oral intake of aluminium or zinc does not accelerate Alzheimer pathology in AÎ²PP and AÎ²PP/tau transgenic mice. Neuropathology, 2012, 32, 390-397.	0.7	33
523	Translatability scoring in drug development: eight case studies. Journal of Translational Medicine, 2012, 10, 39.	1.8	37
524	Non-Steroidal Anti-Inflammatory Drugs and Cognitive Function: Are Prostaglandins at the Heart of Cognitive Impairment in Dementia and Delirium ?. Journal of NeuroImmune Pharmacology, 2012, 7, 60-73.	2.1	46
525	Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica, 2012, 123, 13-30.	3.9	189
526	Progress in Alzheimerâ€™s disease. Journal of Neurology, 2012, 259, 201-211.	1.8	79
527	Microglia and neurodegeneration: The role of systemic inflammation. Glia, 2013, 61, 71-90.	2.5	626
528	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immunity and Ageing, 2013, 10, 18.	1.8	97
529	Neuroimaging of dementia in 2013: what radiologists need to know. European Radiology, 2013, 23, 3393-3404.	2.3	27
530	Is AD a homogeneous nosologic entity? Yes. Journal of Neural Transmission, 2013, 120, 1467-1473.	1.4	0

#	Article	IF	Citations
531	Treatment of Alzheimerâ€™s Disease: Current Management and Experimental Therapeutics. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 174-181.	0.7	11
532	Novel disease-modifying therapeutics for the treatment of Alzheimerâ€™s disease. Expert Review of Clinical Pharmacology, 2013, 6, 423-442.	1.3	7
533	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Progress in Neurobiology, 2013, 108, 21-43.	2.8	499
534	Synthetic AÎ² oligomers (AÎ²1â€“42 globulomer) modulate presynaptic calcium currents: Prevention of AÎ²-induced synaptic deficits by calcium channel blockers. European Journal of Pharmacology, 2013, 702, 44-55.	1.7	32
535	A canine model of human aging and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1384-1389.	1.8	98
536	Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochemical Pharmacology, 2013, 86, 862-871.	2.0	21
537	Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. , 2013, 9, e17-e73.		30
538	Voluntary exercise counteracts AÎ²25-35-induced memory impairment in mice. Behavioural Brain Research, 2013, 256, 618-625.	1.2	35
539	Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease. Pharmacology Biochemistry and Behavior, 2013, 107, 48-57.	1.3	23
540	A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation AÎ²42 DNA vaccine for Alzheimer disease. Journal of Neuroimmunology, 2013, 254, 63-68.	1.1	29
541	Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E517-25.	3.3	401
542	Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?. Expert Opinion on Biological Therapy, 2013, 13, 1515-1522.	1.4	20
543	Current and Emerging Therapies for Alzheimerâ€™s Disease. Clinical Therapeutics, 2013, 35, 1480-1489.	1.1	28
544	Immunotherapy for neurodegenerative diseases: Focus on Î±-synucleinopathies. , 2013, 138, 311-322.		115
545	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathologica, 2013, 126, 479-497.	3.9	366
546	Drug development in dementia. Maturitas, 2013, 76, 260-266.	1.0	3
547	<scp>CD</scp>4 <scp>T</scp> cells in immunity and immunotherapy of <scp>A</scp>lzheimer's disease. Immunology, 2013, 139, 438-446.	2.0	56
548	TraitÃ© sur la maladie dâ€™Alzheimer. , 2013, , .		0

#	Article	IF	Citations
549	Immunotherapy for Alzheimerâ€™s disease: hoops and hurdles. Molecular Neurodegeneration, 2013, 8, 36.	4.4	162
550	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	2.4	138
551	Immunomodulation targeting of both AÎ² and tau pathological conformers ameliorates Alzheimerâ€™s disease pathology in TgSwDI and 3xTg mouse models. Journal of Neuroinflammation, 2013, 10, 150.	3.1	47
552	Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?. Journal of Alzheimer's Disease, 2013, 38, 719-740.	1.2	40
553	Caspaseâ€6 as a novel early target in the treatment of Alzheimer's disease. European Journal of Neuroscience, 2013, 37, 2005-2018.	1.2	49
554	Therapeutic strategies for tau mediated neurodegeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 784-795.	0.9	115
555	Combining Multiple Markers to Improve the Longitudinal Rate of Progression: Application to Clinical Trials on the Early Stage of Alzheimer's Disease. Statistics in Biopharmaceutical Research, 2013, 5, 54-66.	0.6	11
556	Interaction of Cinnamaldehyde and Epicatechin with Tau: Implications of Beneficial Effects in Modulating Alzheimer's Disease Pathogenesis. Journal of Alzheimer's Disease, 2013, 36, 21-40.	1.2	91
557	Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiology of Aging, 2013, 34, 169-183.	1.5	74
558	Immunization targeting a minor plaque constituent clears Î²-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. Neurobiology of Aging, 2013, 34, 137-145.	1.5	33
559	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs. Journal of Alzheimer's Disease, 2013, 34, 1-114.	1.2	23
560	What have we learned from the streptozotocin-induced animal model of sporadic Alzheimerâ€™s disease, about the therapeutic strategies in Alzheimerâ€™s research. Journal of Neural Transmission, 2013, 120, 233-252.	1.4	220
561	Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiology of Aging, 2013, 34, 2613-2622.	1.5	32
562	Fortress Brain. Medical Hypotheses, 2013, 80, 118-121.	0.8	1
563	A milestone on the way to therapy for MSA. Lancet Neurology, The, 2013, 12, 222-223.	4.9	2
564	Reduction of cerebral AÎ² burden and improvement in cognitive function in Tg-APPswe/PSEN1dE9 mice following vaccination with a multivalent AÎ²3â€“10 DNA vaccine. Neuroscience Letters, 2013, 549, 109-115.	1.0	5
565	Combination of AÎ² clearance and neurotrophic factors as a potential treatment for Alzheimerâ€™s disease. Neuroscience Bulletin, 2013, 29, 111-120.	1.5	9
566	Hopeahainol <scp>A</scp> attenuates memory deficits by targeting Î²â€amyloid in <scp>APP</scp>/<scp>PS</scp>1 transgenic mice. Aging Cell, 2013, 12, 85-92.	3.0	22

#	Article	IF	Citations
567	Review: Systemic inflammation and <scp>A</scp>lzheimer's disease. Neuropathology and Applied Neurobiology, 2013, 39, 51-68.	1.8	282
568	Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. Journal of Neuroscience, 2013, 33, 4923-4934.	1.7	100
569	Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease. Journal of Medicinal Chemistry, 2013, 56, 4135-4155.	2.9	105
570	Sustained Interleukin-1Î² Overexpression Exacerbates Tau Pathology Despite Reduced Amyloid Burden in an Alzheimer's Mouse Model. Journal of Neuroscience, 2013, 33, 5053-5064.	1.7	310
571	<scp>A</scp>lzheimer's Disease Biomarkers: More Than Molecular Diagnostics. Drug Development Research, 2013, 74, 92-111.	1.4	6
572	Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesisâ€"but what lies beyond?. Biochemical Pharmacology, 2013, 85, 289-305.	2.0	181
573	Antiâ€"amyloid Î² autoantibodies in cerebral amyloid angiopathyâ€"related inflammation: Implications for amyloidâ€modifying therapies. Annals of Neurology, 2013, 73, 449-458.	2.8	179
574	Immunotherapy against amyloid pathology in Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 50-54.	0.3	38
575	Immunotherapy in Alzheimerâ€™s Disease: Do We Have All the Pieces of the Puzzle?. Biological Psychiatry, 2013, 74, 329-332.	0.7	30
576	Active vaccination with ankyrin G reduces Î²-amyloid pathology in APP transgenic mice. Molecular Psychiatry, 2013, 18, 358-368.	4.1	23
577	Differential X-ray phase contrast tomography of Alzheimer plaques in mouse models: perspectives for drug development and clinical imaging techniques. Journal of Instrumentation, 2013, 8, C05005-C05005.	0.5	1
579	Alzheimer's disease: which type of amyloid-preventing drug agents to employ?. Physical Chemistry Chemical Physics, 2013, 15, 8868.	1.3	50
580	Rational heterodoxy: Cholesterol reformation of the amyloid doctrine. Ageing Research Reviews, 2013, 12, 282-288.	5.0	33
581	The effect of fulvic acid on preâ€and postaggregation state of AÎ²17â€"42: Molecular dynamics simulation studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 24-33.	1.1	13
582	Immunogenic properties of amyloid beta oligomers. Journal of Biomedical Science, 2013, 20, 10.	2.6	12
583	Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimerâ€™s disease. Brain, 2013, 136, 844-858.	3.7	280
584	Immunotherapy for Alzheimerâ€™s Disease. Neurologic Clinics, 2013, 31, 869-878.	0.8	20
585	Detecting amyloid biomarkers: Embodied risk and Alzheimer prevention. BioSocieties, 2013, 8, 107-123.	0.8	9

#	Article	IF	Citations
586	Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies. Current Drug Targets, 2013, 14, 114-122.	1.0	32
587	Inflammatory components in human Alzheimerâ€™s disease and after active amyloid-Î²42 immunization. Brain, 2013, 136, 2677-2696.	3.7	234
588	Individual Classification of Mild Cognitive Impairment Subtypes by Support Vector Machine Analysis of White Matter DTI. American Journal of Neuroradiology, 2013, 34, 283-291.	1.2	45
589	An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment. American Journal of Neuroradiology, 2013, 34, 2075-2082.	1.2	24
590	DNA AÎ²42 Vaccination as Possible Alternative Immunotherapy for Alzheimer Disease. JAMA Neurology, 2013, 70, 772.	4.5	8
591	Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?. ImmunoTargets and Therapy, 2014, 3, 19.	2.7	11
592	Alzheimer Disease Pharmacologic Treatment and Treatment Research. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 339-357.	0.4	26
593	Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects. Alzheimer Disease and Associated Disorders, 2013, 27, 278-286.	0.6	34
594	New Genes and New Insights from Old Genes. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 358-371.	0.4	15
595	Cinnamon Counteracts the Negative Effects of a High Fat/High Fructose Diet on Behavior, Brain Insulin Signaling and Alzheimer-Associated Changes. PLoS ONE, 2013, 8, e83243.	1.1	53
596	Î³-Secretase â€" Regulated Signaling and Alzheimer's Disease. , 2013, , .		0
597	Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Scientific Reports, 2013, 3, 1472.	1.6	83
598	Inflammation in Alzheimerâ€™s disease: insights from immunotherapy. Brain, 2013, 136, 2654-2656.	3.7	38
599	Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology. Journal of Biological Chemistry, 2013, 288, 33081-33095.	1.6	141
600	Molecular Pathology of Alzheimer's Disease. Colloquium Series on Neurobiology of Alzheimer S Disease, 2013, 1, 1-91.	0.0	4
601	Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology. Expert Opinion on Biological Therapy, 2013, 13, 1639-1641.	1.4	11
602	Translational research on diseaseâ€modifying therapies for neurodegenerative diseases. Neurology and Clinical Neuroscience, 2013, 1, 3-10.	0.2	4
603	Diseaseâ€modifying therapy for Alzheimer's disease: Challenges and hopes. Neurology and Clinical Neuroscience, 2013, 1, 49-54.	0.2	9

#	Article	IF	Citations
604	Semagacestat's fall: where next for AD therapies?. Nature Medicine, 2013, 19, 1214-1215.	15.2	18
605	Refinement of a DNA based Alzheimer disease epitope vaccine in rabbits. Human Vaccines and Immunotherapeutics, 2013, 9, 1002-1010.	1.4	28
607	Alzheimerâ€™s pathology: should peripheral monocytes and CCR2 take center stage?. Neurodegenerative Disease Management, 2013, 3, 9-12.	1.2	1
608	Mass Transfer and Computational Fluid-dynamics in Bioreactors. , 2013, , 460-486.		0
609	Progression of mild Alzheimerâ€™s disease: knowledge and prediction models required for future treatment strategies. Alzheimer's Research and Therapy, 2013, 5, 44.	3.0	28
610	What can we learn from regional vulnerability to amyloid-Î² accumulation in nondemented individuals?. Neurodegenerative Disease Management, 2013, 3, 187-189.	1.2	2
611	The role of APP in Alzheimerâ€™s disease. Advances in Alzheimer's Disease, 2013, 02, 60-65.	0.3	2
612	Axonal and Dendritic Changes are Associated with Diabetic Encephalopathy in Rats: An Important Risk Factor for Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 937-947.	1.2	29
613	Medicine, 2013, 102, 112b-113a.	0.0	0
616	Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease. Revista Brasileira De Psiquiatria, 2013, 35, 284-294.	0.9	18
617	Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease. ImmunoTargets and Therapy, 2013, 2013, 105.	2.7	32
618	Disease-modifying drugs in Alzheimer's disease. Drug Design, Development and Therapy, 2013, 7, 1471.	2.0	55
619	Improved Design of Prodromal Alzheimer's Disease Trials through Cohort Enrichment and Surrogate Endpoints. Journal of Alzheimer's Disease, 2013, 36, 475-486.	1.2	6
620	Bapineuzumab Alters AÎ² Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy. PLoS ONE, 2013, 8, e59735.	1.1	30
621	Cellular and animal models for high-throughput screening of therapeutic agents for the treatment of the diseases of the elderly in general and Alzheimerâ€™s disease in particularâ€. Frontiers in Pharmacology, 2013, 4, 59.	1.6	5
622	Therapy in Prion Diseases. Current Topics in Medicinal Chemistry, 2013, 13, 2465-2476.	1.0	41
623	Tau aggregates as immunotherapeutic targets. Frontiers in Bioscience - Scholar, 2013, S5, 426-438.	0.8	31
624	Alzheimer's disease and periodontitis - an elusive link. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2014, 60, 173-180.	0.3	37

#	Article	IF	Citations
625	Alum and Squalene-Oil-in-Water Emulsion Enhance the Titer and Avidity of Anti-AÎ² Antibodies Induced by Multimeric Protein Antigen (1â€“11)E2, Preserving the Igg1-Skewed Isotype Distribution. PLoS ONE, 2014, 9, e101474.	1.1	16
626	RCAN1 Regulates Mitochondrial Function and Increases Susceptibility to Oxidative Stress in Mammalian Cells. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-12.	1.9	26
627	Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. Journal of Korean Medical Science, 2014, 29, 893.	1.1	21
628	Prevention approaches in a preclinical canine model of AlzheimerÃ¢â‚¬â„¢s disease: benefits and challenges. Frontiers in Pharmacology, 2014, 5, 47.	1.6	32
629	Possible modification of AlzheimerÃ¢â‚¬â„¢s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Frontiers in Aging Neuroscience, 2014, 6, 71.	1.7	43
630	Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies. Korean Journal of Physiology and Pharmacology, 2014, 18, 447.	0.6	13
631	TL-2 attenuates Î²-amyloid induced neuronal apoptosis through the AKT/GSK-3Î²/Î²-catenin pathway. International Journal of Neuropsychopharmacology, 2014, 17, 1511-1519.	1.0	30
632	D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. Prion, 2014, 8, 119-124.	0.9	40
633	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology, 2014, 10, 405-419.	1.3	86
634	Qifu-Yin attenuates AGEs-induced Alzheimer-like pathophysiological changes through the RAGE/NF-ÎºB pathway. Chinese Journal of Natural Medicines, 2014, 12, 920-928.	0.7	15
635	Aging, Overview. , 2014, , 76-80.		1
636	Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review. Gerontology, 2014, 60, 381-385.	1.4	84
637	The â€œMemory Kinasesâ€• Progress in Molecular Biology and Translational Science, 2014, 122, 31-59.	0.9	76
638	Amyloid beta peptide immunotherapy in Alzheimer disease. Revue Neurologique, 2014, 170, 739-748.	0.6	25
639	A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-Î²-amyloid antibody responses in mice with pre-existing virus specific memory. Journal of Neuroimmunology, 2014, 277, 77-84.	1.1	4
640	Clinical trials and lateâ€stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine, 2014, 275, 251-283.	2.7	540
641	Lessons Learned from Major Clinical Trials Conducted Over the Past Decades. , 2014, , 77-97.		3
642	AÎ² immunotherapy for Alzheimerâ€™s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathologica, 2014, 128, 777-789.	3.9	44

#	Article	IF	Citations
643	Structureâ€“Function Studies of Amyloid Pores in Alzheimerâ€™s Disease as a Case Example of Neurodegenerative Diseases. , 2014, , 397-408.		0
644	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Current Opinion in Psychiatry, 2014, 27, 128-137.	3.1	86
645	Vaccination against Alzheimer disease. Human Vaccines and Immunotherapeutics, 2014, 10, 847-851.	1.4	33
646	Why the Negative Studies in Alzheimerâ€™s Disease?. , 2014, , 99-116.		0
647	Magnetic resonance imaging for monitoring therapeutic response in a transgenic mouse model of Alzheimerâ€™s disease using voxel-based analysis of amyloid plaques. NeuroReport, 2014, 25, 211-218.	0.6	8
648	The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1219-1231.	1.8	557
649	Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study. International Journal of Food Sciences and Nutrition, 2014, 65, 89-96.	1.3	33
650	Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology, 2014, 76, 27-50.	2.0	601
651	Cell Signaling Abnormalities May Drive Neurodegeneration in Familial Alzheimer Disease. Neurochemical Research, 2014, 39, 570-575.	1.6	9
652	Biomarkers in Amyloid-Î² Immunotherapy Trials in Alzheimerâ€™s Disease. Neuropsychopharmacology, 2014, 39, 189-201.	2.8	66
653	Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. Journal of Neuroimmunology, 2014, 268, 50-57.	1.1	8
654	Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nature Reviews Neuroscience, 2014, 15, 300-312.	4.9	1,069
655	Considering a new paradigm for Alzheimer's disease research. Drug Discovery Today, 2014, 19, 1114-1124.	3.2	33
656	The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Letters, 2014, 588, 641-652.	1.3	53
657	Alzheimerâ€™s disease: analysis of a mathematical model incorporating the role of prions. Journal of Mathematical Biology, 2014, 69, 1207-1235.	0.8	44
658	Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis. Biochemical Pharmacology, 2014, 88, 486-494.	2.0	55
659	Immunotherapy for Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 499-507.	2.0	90
660	Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment. Cell Death and Differentiation, 2014, 21, 696-706.	5.0	45

#	Article	IF	Citations
661	Pyrazole-5-carboxamides, novel inhibitors of receptor for advanced glycation end products (RAGE). European Journal of Medicinal Chemistry, 2014, 79, 128-142.	2.6	60
662	Alzheimerâ€™s and ABC transporters â€" new opportunities for diagnostics and treatment. Neurobiology of Disease, 2014, 72, 54-60.	2.1	66
663	The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. Brain Research, 2014, 1551, 25-44.	1.1	30
664	The role of inflammasome in Alzheimer's disease. Ageing Research Reviews, 2014, 15, 6-15.	5.0	162
665	Tau acts as a mediator for <scp>A</scp>lzheimer's diseaseâ€related synaptic deficits. European Journal of Neuroscience, 2014, 39, 1202-1213.	1.2	43
666	Head Motion Parameters in fMRI Differ Between Patients with Mild Cognitive Impairment and Alzheimer Disease Versus Elderly Control Subjects. Brain Topography, 2014, 27, 801-807.	0.8	21
667	Oleuropein aglycone counteracts AÎ²42 toxicity in the rat brain. Neuroscience Letters, 2014, 558, 67-72.	1.0	66
668	Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures. European Journal of Pharmacology, 2014, 739, 83-95.	1.7	72
669	Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 529-539.	2.0	221
670	Emerging Therapeutics for Alzheimer's Disease. Annual Review of Pharmacology and Toxicology, 2014, 54, 381-405.	4.2	76
671	Beta-amyloid auto-antibodies are reduced in Alzheimer's disease. Journal of Neuroimmunology, 2014, 274, 168-173.	1.1	42
672	Alzheimerâ€™s Disease, Anesthesia, and Surgery: A Clinically Focused Review. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1609-1623.	0.6	39
673	Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to Treatment. NeuroImmunoModulation, 2014, 21, 79-87.	0.9	74
674	Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model. Neurobiology of Aging, 2014, 35, 2736-2745.	1.5	27
675	Molecular drug targets and therapies for Alzheimerâ€™s disease. Translational Neuroscience, 2014, 5, .	0.7	17
676	Alzheimer's disease: still a perplexing problem. BMJ, The, 2014, 349, g4433-g4433.	3.0	9
677	Open questions for Alzheimerâ€™s disease immunotherapy. Alzheimer's Research and Therapy, 2014, 6, 3.	3.0	77
678	Interpreting Alzheimerâ€™s disease clinical trials in light of the effects on amyloid-Î². Alzheimer's Research and Therapy, 2014, 6, 14.	3.0	30

#	Article	IF	Citations
679	Conformation-specific antibodies to target amyloid Î² oligomers and their application to immunotherapy for Alzheimerâ€™s disease. Bioscience, Biotechnology and Biochemistry, 2014, 78, 1293-1305.	0.6	37
680	Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 787-801.	3.9	129
681	Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimerâ€™s Disease. Journal of Clinical Immunology, 2014, 34, 80-85.	2.0	21
682	Phenotypic profile of alternative activation marker CD163 is different in Alzheimerâ€™s and Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 21.	2.4	102
683	The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 372-380.	0.4	189
684	Cerebrospinal fluid biomarkers of Alzheimerâ€™s disease. Neuroscience Bulletin, 2014, 30, 233-242.	1.5	16
685	Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs. Chemical Society Reviews, 2014, 43, 6750-6764.	18.7	80
686	Latest treatment options for Alzheimerâ€™s disease, Parkinsonâ€™s disease dementia and dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2014, 15, 1797-1810.	0.9	50
687	Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and <scp>A</scp>lzheimer disease. Annals of Neurology, 2014, 76, 813-825.	2.8	91
688	Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimerâ€™s disease model. Neurobiology of Disease, 2014, 68, 126-136.	2.1	126
689	Pathogenesis of Alzheimerâ€™s Disease. , 2014, , 2327-2337.		1
690	The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. , 2014, 10, 271-283.		23
691	Danshen diversity defeating dementia. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 708-716.	1.0	43
692	DNA Vaccines. Methods in Molecular Biology, 2014, , .	0.4	5
693	Memory Deficits in Aging and Neurological Diseases. Progress in Molecular Biology and Translational Science, 2014, 122, 1-29.	0.9	29
694	A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Annals of Neurology, 2014, 76, 185-205.	2.8	232
695	Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane Library, 2014, , CD008782.	1.5	88
696	p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neuroscience Letters, 2014, 575, 96-100.	1.0	48

#	Article	IF	Citations
697	Specific binding of intravenous immunoglobulin products to tau peptide fragments. International Immunopharmacology, 2014, 21, 279-282.	1.7	11
698	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimerâ€™s Disease. Neuron, 2014, 82, 756-771.	3.8	862
699	Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet, The, 2014, 384, 504-513.	6.3	129
700	Salidroside Protects Caenorhabditis elegans Neurons from Polyglutamine-Mediated Toxicity by Reducing Oxidative Stress. Molecules, 2014, 19, 7757-7769.	1.7	48
701	Harnessing the Immune System for Treatment and Detection of Tau Pathology. Journal of Alzheimer's Disease, 2014, 40, S113-S121.	1.2	18
703	Vaccination with Sarkosyl Insoluble PHF-Tau Decrease Neurofibrillary Tangles Formation in Aged Tau Transgenic Mouse Model: A Pilot Study. Journal of Alzheimer's Disease, 2014, 40, S135-S145.	1.2	18
704	Clinical Trials and Drug Development. Cancer Control, 2014, 21, 188-189.	0.7	1
705	Improvement of Memory Deficits and Amyloid-Î² Clearance in Aged APP23 Mice Treated with a Combination of Anti-Amyloid-Î² Antibody and LXR Agonist. Journal of Alzheimer's Disease, 2014, 41, 535-549.	1.2	28
706	P2-030: INVESTIGATING THE ROLE OF CLU, PICALM, AND CR1 IN ALZHEIMER'S DISEASE. , 2014, 10, P481-P481.		0
707	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	1.7	32
708	Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nature Communications, 2015, 6, 10216.	5.8	94
709	Alzheimerâ€™s Disease Cerebrospinal Fluid andÂNeuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. Journal of Alzheimer's Disease, 2015, 46, 817-836.	1.2	47
713	An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. Journal of Neuroinflammation, 2015, 12, 153.	3.1	29
714	Immunotherapy in Parkinsonâ€™s Disease: Micromanaging Alpha-Synuclein Aggregation. Journal of Parkinson's Disease, 2015, 5, 413-424.	1.5	69
716	A Current Understanding of Alzheimers Disease and the Prospects of Phytopharmacological Intervention as a Management Strategy. Journal of Neurological Disorders, 2015, 03, .	0.1	0
717	Amyloid Burden in Cognitively Normal Elderly is Associated with Preferential Hippocampal Subfield Volume Loss. Journal of Alzheimer's Disease, 2015, 45, 27-33.	1.2	44
718	Alzheimerâ€™s Disease: Mechanism and Approach to Cell Therapy. International Journal of Molecular Sciences, 2015, 16, 26417-26451.	1.8	82
719	On the central role of brain connectivity in neurodegenerative disease progression. Frontiers in Aging Neuroscience, 2015, 7, 90.	1.7	53

#	Article	IF	Citations
720	Fluid Biomarkers in Clinical Trials of Alzheimerâ€™s Disease Therapeutics. Frontiers in Neurology, 2015, 6, 186.	1.1	22
721	Misframed ubiquitin and impaired protein quality control: an early event in Alzheimerâ€™s disease. Frontiers in Molecular Neuroscience, 2015, 8, 47.	1.4	34
722	A Reduced Astrocyte Response to Î²-Amyloid Plaques in the Ageing Brain Associates with Cognitive Impairment. PLoS ONE, 2015, 10, e0118463.	1.1	45
723	Porphyromonas gingivalisPeriodontal Infection and Its Putative Links with Alzheimerâ€™s Disease. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	153
724	The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced AmyloidÎ²Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. Journal of Immunology Research, 2015, 2015, 1-9.	0.9	5
725	A Comparative Evaluation of a Novel Vaccine in APP/PS1 Mouse Models of Alzheimerâ€™s Disease. BioMed Research International, 2015, 2015, 1-16.	0.9	13
726	Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?. ImmunoTargets and Therapy, 2015, 4, 27.	2.7	14
727	T Cellsâ€”Protective or Pathogenic in Alzheimerâ€™s Disease?. Journal of NeuroImmune Pharmacology, 2015, 10, 547-560.	2.1	42
728	The case for rejecting the amyloid cascade hypothesis. Nature Neuroscience, 2015, 18, 794-799.	7.1	613
729	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience, 2015, 18, 800-806.	7.1	582
730	Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties. Biochemistry (Moscow), 2015, 80, 1800-1819.	0.7	31
731	Preventing Alzheimer's disease by means of natural selection. Journal of the Royal Society Interface, 2015, 12, 20140919.	1.5	21
733	A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth. Neuropharmacology, 2015, 92, 146-157.	2.0	13
734	Neurotoxicity and synaptic plasticity impairment of N-acetylglucosamine polymers: implications for Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1780-1791.	1.5	17
735	Cortical hypermetabolism in MCI subjects: a compensatory mechanism?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 447-458.	3.3	99
736	Effects of Tau Domain-Specific Antibodies and Intravenous Immunoglobulin on Tau Aggregation and Aggregate Degradation. Biochemistry, 2015, 54, 293-302.	1.2	11
737	Cognitive recovery by chronic activation of the large-conductance calcium-activated potassium channel in a mouse model of Alzheimer's disease. Neuropharmacology, 2015, 92, 8-15.	2.0	46
738	Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. Journal of Neural Transmission, 2015, 122, 607-617.	1.4	79

#	Article	IF	Citations
739	Effect of amyloidâ€Î²2 (<scp>A</scp>Î²2) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase <scp>(GSK</scp>)â€3Î²2. Neuropathology and Applied Neurobiology, 2015, 41, 445-457.	1.8	17
740	Biomarkers for glioma immunotherapy: the next generation. Journal of Neuro-Oncology, 2015, 123, 359-372.	1.4	23
741	The Role of PICALM in Alzheimerâ€™s Disease. Molecular Neurobiology, 2015, 52, 399-413.	1.9	81
742	A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1246-1259.	0.4	50
743	Slowing the progression of Alzheimerâ€™s disease; what works?. Ageing Research Reviews, 2015, 23, 193-209.	5.0	71
744	Exercise, cognitive function, and aging. American Journal of Physiology - Advances in Physiology Education, 2015, 39, 55-62.	0.8	198
745	Inflammation in Alzheimerâ€™s Disease and Molecular Genetics: Recent Update. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 333-344.	1.0	67
746	Reducing AÎ2 load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. European Journal of Pharmacology, 2015, 764, 571-581.	1.7	42
747	Improvement of spatial learning by facilitating large-conductance calcium-activated potassium channel with transcranial magnetic stimulation in Alzheimer's disease model mice. Neuropharmacology, 2015, 97, 210-219.	2.0	63
748	Current and future implications of basic and translational research on amyloid-Î2 peptide production and removal pathways. Molecular and Cellular Neurosciences, 2015, 66, 3-11.	1.0	56
749	Long-term treatment with active AÎ2 immunotherapy with CAD106 in mild Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 23.	3.0	112
750	A noninflammatory immune response in aged DNA AÎ2 42-immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiology of Aging, 2015, 36, 1274-1281.	1.5	13
751	Immunotherapeutic Approaches for Alzheimerâ€™s Disease. Neuron, 2015, 85, 1162-1176.	3.8	241
752	Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation. Neurochemical Research, 2015, 40, 1032-1041.	1.6	4
753	Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimer's Research and Therapy, 2015, 7, 33.	3.0	150
754	Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience, 2015, 16, 358-372.	4.9	1,677
755	Amyloid Î2: one of three dangerâ€associated molecules that are secondary inducers of the proinflammatory cytokines that mediate <scp>A</scp>lzheimer's disease. British Journal of Pharmacology, 2015, 172, 3714-3727.	2.7	71
756	Acute amnestic encephalopathy in amyloid-Î2 oligomerâ€“injected mice is due to their widespread diffusion inÂvivo. Neurobiology of Aging, 2015, 36, 2043-2052.	1.5	23

#	Article	IF	Citations
757	Towards universal therapeutics for memory disorders. Trends in Pharmacological Sciences, 2015, 36, 384-394.	4.0	44
758	From Neurodegeneration to Brain Health: AnÂIntegrated Approach. Journal of Alzheimer's Disease, 2015, 46, 271-283.	1.2	6
759	Cannabinoids in lateâ€onset Alzheimer's disease. Clinical Pharmacology and Therapeutics, 2015, 97, 597-606.	2.3	38
760	Impact of amyloid Î² aggregate maturation on antibody treatment in APP23 mice. Acta Neuropathologica Communications, 2015, 3, 41.	2.4	13
761	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegenerative Disease Management, 2015, 5, 425-443.	1.2	28
762	Immunotherapy Applied to Neuropsychiatric Disorders: a New Perspective of Treatment. Journal of Molecular Neuroscience, 2015, 57, 139-141.	1.1	1
763	Neurodegenerative Disorders as Systemic Diseases. , 2015, , .		2
764	A decade of discovery and disappointment in dementia research. Nature Reviews Neurology, 2015, 11, 613-614.	4.9	3
765	GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimerâ€™s Disease. ACS Nano, 2015, 9, 10801-10816.	7.3	94
766	Structureâ€“Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimerâ€™s Disease Brains. Journal of Medicinal Chemistry, 2015, 58, 7241-7257.	2.9	41
767	Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations. Human Vaccines and Immunotherapeutics, 2015, 11, 1921-1926.	1.4	13
768	Targeting protein aggregation for the treatment of degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 759-780.	21.5	338
769	Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. Journal of Immunological Methods, 2015, 424, 64-79.	0.6	15
770	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
771	Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiology of Aging, 2015, 36, 627-633.	1.5	198
772	The combined treatment of amyloid-Î²1-42-stimulated bone marrowâ€“derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice. Neurobiology of Aging, 2015, 36, 111-122.	1.5	17
773	Effect of active AÎ² immunotherapy on neurons in human Alzheimer's disease. Journal of Pathology, 2015, 235, 721-730.	2.1	31
774	Emerging Concepts in Alzheimer's Disease. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 291-319.	9.6	211

#	Article	IF	Citations
775	Amyloid-Beta Disrupts Calcium and Redox Homeostasis in Brain Endothelial Cells. Molecular Neurobiology, 2015, 51, 610-622.	1.9	46
776	Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?. European Neuropsychopharmacology, 2015, 25, 713-724.	0.3	78
777	Biometals and Their Therapeutic Implications in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 109-120.	2.1	109
778	Î²-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 3-11.	2.1	195
779	Novel Transgenic Rice-Based Vaccines. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 87-99.	1.0	25
780	A century of confusion in researching Alzheimerâ€™s disease. International Journal of Healthcare, 2016, 2, .	0.2	4
782	Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 809-816.	0.7	5
783	Membrane-Associated Diseases. , 2016, , 499-519.		3
784	Anti-AÎ² Antibodies in the Fighting with Alzheimerâ€™s Disease. Single Cell Biology, 2016, 05, .	0.2	1
785	The New Criteria for Alzheimerâ€™s Disease - Implications for Geriatricians*. Canadian Geriatrics Journal, 2016, 19, 66-73.	0.7	14
786	Nutritional and Methodological Perspectives of Zinc Ions and Complexes - Physiological and Pathological States. International Journal of Electrochemical Science, 2016, , 4470-4496.	0.5	4
787	A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate AÎ² Peptides. Molecular Medicine, 2016, 22, 841-849.	1.9	7
788	Molecular Mechanisms in the Pathogenesis of Alzheimerâ€™s disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation. Biomolecules, 2016, 6, 24.	1.8	53
789	The Rationale for Insulin Therapy in Alzheimerâ€™s Disease. Molecules, 2016, 21, 689.	1.7	14
790	Treatment of Alzheimer's Disease with Repetitive Transcranial Magnetic Stimulation Combined with Cognitive Training: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. Journal of		

#	Article	IF	Citations
794	The amyloid cascade hypothesis: are we poised for success or failure?. Journal of Neurochemistry, 2016, 139, 237-252.	2.1	308
795	Probing amyloid beta-induced cell death using a fluorescence-peptide conjugate in Alzheimer's disease mouse model. Brain Research, 2016, 1646, 514-521.	1.1	5
796	Immunotherapy targeting pyroglutamate-3 AÎ²: prospects and challenges. Molecular Neurodegeneration, 2016, 11, 48.	4.4	38
797	Structure of ring-shaped AÎ²42 oligomers determined by conformational selection. Scientific Reports, 2016, 6, 21429.	1.6	32
798	An Oral AÎ² Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in AÎ² Oligomers. Journal of Alzheimer's Disease, 2016, 54, 1047-1059.	1.2	21
799	Familial Presenilin Mutations and Sporadic Alzheimerâ€™s Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?. Journal of Alzheimer's Disease, 2016, 50, 645-658.	1.2	16
800	Two Phase 2 Multiple Ascendingâ€“Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 1131-1143.	1.2	78
801	Influence of Low-Dose Aspirin on Cerebral Amyloid Angiopathy in Mice. Journal of Alzheimer's Disease, 2016, 52, 1037-1045.	1.2	8
803	Curcumin improves tau-induced neuronal dysfunction of nematodes. Neurobiology of Aging, 2016, 39, 69-81.	1.5	43
804	A Novel AÎ² B-Cell Epitope Vaccine (rCV01) for Alzheimerâ€™s Disease Improved Synaptic and Cognitive Functions in 3ÂÃ—ÂTg-AD Mice. Journal of NeuroImmune Pharmacology, 2016, 11, 657-668.	2.1	12
805	Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimerâ€™s Disease. Neuroscience Bulletin, 2016, 32, 591-596.	1.5	40
806	Dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 138, 123-151.	1.0	35
807	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opinion on Drug Discovery, 2016, 11, 939-956.	2.5	10
808	The endocytic pathway in microglia during health, aging and Alzheimerâ€™s disease. Ageing Research Reviews, 2016, 32, 89-103.	5.0	93
809	The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature, 2016, 539, 187-196.	13.7	426
810	Monoclonal antibody with conformational specificity for a toxic conformer of amyloid Î²42 and its application toward the Alzheimerâ€™s disease diagnosis. Scientific Reports, 2016, 6, 29038.	1.6	50
812	Mitochondrial Dysfunction in Neurodegenerative Disorders. , 2016, , .		3
813	Anti-Amyloid-Î² Immunotherapy for Alzheimerâ€™s Disease. , 2016, , 193-226.		9

#	Article	IF	Citations
814	Tackling Alzheimerâ€™s Disease by Targeting Oxidative Stress and Mitochondria. , 2016, , 477-502.		1
815	Clinical Issues in Alzheimer DrugÂDevelopment. , 2016, , 503-521.		1
816	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2
817	Genetic variants in Alzheimer disease â€" molecular and brain network approaches. Nature Reviews Neurology, 2016, 12, 413-427.	4.9	97
818	Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience and Biobehavioral Reviews, 2016, 68, 547-562.	2.9	114
819	Small molecule NPT-440-1 inhibits ionic flux through AÎ² 1-42 pores: Implications for Alzheimer's disease therapeutics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2331-2340.	1.7	1
820	Immunotherapy Against Amyloid-Î² in Alzheimerâ€™s Disease: An Overview. Methods in Pharmacology and Toxicology, 2016, , 3-17.	0.1	1
821	Active Immunization Against the Amyloid-Î² Peptide. Methods in Pharmacology and Toxicology, 2016, , 19-35.	0.1	0
822	Tau Immunotherapy. Methods in Pharmacology and Toxicology, 2016, , 109-120.	0.1	1
823	Mitochondrial Signaling and Neurodegeneration. , 2016, , 107-137.		6
824	Alzheimerâ€™s Turning Point. , 2016, , .		8
825	AÎ²-Degrading Proteases: Therapeutic Potential in Alzheimer Disease. CNS Drugs, 2016, 30, 667-675.	2.7	22
826	Emerging amyloid disease-modifying drugs for Alzheimerâ€™s disease. Expert Opinion on Emerging Drugs, 2016, 21, 5-7.	1.0	10
827	Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimerâ€™s Disease Through Activation of Canonical Wnt/Î²-Catenin Signalling Pathway. Neurotoxicity Research, 2016, 29, 495-513.	1.3	11
828	Positive modulators of the Î±7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. Progress in Neurobiology, 2016, 144, 142-157.	2.8	85
829	Learning impairment by minimal cortical injury in a mouse model of Alzheimer×³s disease. Brain Research, 2016, 1637, 56-63.	1.1	5
830	Symptomatic and preclinical Alzheimerâ€™s disease: Neuropathology and imaging. Neurology Psychiatry and Brain Research, 2016, 22, 127-131.	2.0	2
831	Practical Pharmacology for Alzheimerâ€™s Disease. , 2016, , .		2

#	Article	IF	Citations
832	C-Terminal Fragment, AÎ²_{32â€“37}, Analogues Protect Against AÎ² Aggregation-Induced Toxicity. ACS Chemical Neuroscience, 2016, 7, 615-623.	1.7	30
833	Shengmai Formula Ameliorates Pathological Characteristics in AD C.Âelegans. Cellular and Molecular Neurobiology, 2016, 36, 1291-1302.	1.7	11
834	Basic Theory of Pharmacology for Alzheimerâ€™s Disease. , 2016, , 1-25.		0
835	Immunotherapies in Alzheimerâ€™s disease: Too much, too little, too late or off-target?. Acta Neuropathologica, 2016, 131, 481-504.	3.9	30
836	Developing therapeutic vaccines against Alzheimerâ€™s disease. Expert Review of Vaccines, 2016, 15, 401-415.	2.0	54
837	Alzheimerâ€™s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks. Methods in Molecular Biology, 2016, 1303, 3-48.	0.4	33
838	Why therapies for Alzheimerâ€™s disease do not work: Do we have consensus over the path to follow?. Ageing Research Reviews, 2016, 25, 70-84.	5.0	23
839	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimerâ€™s and Parkinsonâ€™s Diseases. Biosystems and Biorobotics, 2016, , 293-325.	0.2	2
840	Future Treatments of Memory Loss, Alzheimer's Disease, and Dementia. , 2016, , 187-199.		1
841	Reversal of Beta-Amyloid-Induced Neurotoxicity in PC12 Cells by Curcumin, the Important Role of ROS-Mediated Signaling and ERK Pathway. Cellular and Molecular Neurobiology, 2017, 37, 211-222.	1.7	48
842	Two decades of new drug discovery and development for Alzheimer's disease. RSC Advances, 2017, 7, 6046-6058.	1.7	60
843	Update on Alzheimer's Disease Therapy and Prevention Strategies. Annual Review of Medicine, 2017, 68, 413-430.	5.0	402
844	Antibody Therapeutics Targeting AÎ² and Tau. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024331.	2.9	39
845	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. ACS Chemical Neuroscience, 2017, 8, 743-751.	1.7	32
846	Potential importance of B cells in aging and aging-associated neurodegenerative diseases. Seminars in Immunopathology, 2017, 39, 283-294.	2.8	14
847	Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. Biochemical Pharmacology, 2017, 131, 1-15.	2.0	42
848	Biological basis for amyloidogenesis in Alzheimerâ€™S disease. Biochemistry (Moscow), 2017, 82, 122-139.	0.7	25
849	Energy and the Alzheimer brain. Neuroscience and Biobehavioral Reviews, 2017, 75, 297-313.	2.9	32

#	Article	IF	Citations
850	Emerging amyloid and tau targeting treatments for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2017, 17, 697-711.	1.4	11
851	Combined immunotherapy with â€œanti-insulin resistanceâ€•therapy as a novel therapeutic strategy against neurodegenerative diseases. Npj Parkinson's Disease, 2017, 3, 4.	2.5	19
852	Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2017, 37, 5562-5573.	1.7	71
853	Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. , 2017, 172, 22-33.		52
854	Protective effects of flavonoids against Alzheimerâ€™s disease-related neural dysfunctions. Biomedicine and Pharmacotherapy, 2017, 93, 218-229.	2.5	73
855	A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment. Journal of the Taiwan Institute of Chemical Engineers, 2017, 77, 92-105.	2.7	11
856	Alzheimerâ€™s disease: where next for anti-amyloid therapies?. Brain, 2017, 140, 853-855.	3.7	57
857	Revisiting nicotineâ€™s role in the ageing brain and cognitive impairment. Reviews in the Neurosciences, 2017, 28, 767-781.	1.4	25
858	Chitinase1 contributed to a potential protection via microglia polarization and AÎ² oligomer reduction in D-galactose and aluminum-induced rat model with cognitive impairments. Neuroscience, 2017, 355, 61-70.	1.1	23
859	Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimerâ€™s disease. Neuroscience, 2017, 356, 44-51.	1.1	16
860	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
861	Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid Î² (1-42) in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 23-31.	2.5	71
862	Concordance of Several Subcellular Interactions Initiates Alzheimerâ€™s Dementia: Their Reversal Requires Combination Treatment. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 166-181.	0.9	19
863	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Canadian Journal of Neurological Sciences, 2017, 44, 196-202.	0.3	72
864	The synergistic effect between KLVFF and self-assembly chaperones on both disaggregation of beta-amyloid fibrils and reducing consequent toxicity. Chemical Communications, 2017, 53, 1289-1292.	2.2	34
865	Dickkopf 3 (Dkk3) Improves Amyloid-Î² Pathology, Cognitive Dysfunction, and Cerebral Glucose Metabolism in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 733-746.	1.2	21
866	Exploring the Aggregation Mechanism of Intrinsically Disordered Tau Protein. World Scientific Lecture and Course Notes in Chemistry, 2017, , 51-71.	0.2	1
868	Dementia Pugilistica Revisited. Journal of Alzheimer's Disease, 2017, 60, 1209-1221.	1.2	30

#	Article	IF	Citations
869	Amyloid Î²-42 induces neuronal apoptosis by targeting mitochondria. Molecular Medicine Reports, 2017, 16, 4521-4528.	1.1	100
870	Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2017, 43, 553-570.	1.8	46
871	APP/AÎ² structural diversity and Alzheimer's disease pathogenesis. Neurochemistry International, 2017, 110, 1-13.	1.9	78
872	Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to Î² sheet in tau protein linked to Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 945-953.	2.5	63
874	CNS Drug Delivery for Diseases Eradication: An Overview. , 2017, , 157-185.		0
875	Recent Progress in the Pharmacotherapy of Alzheimerâ€™s Disease. Drugs and Aging, 2017, 34, 811-820.	1.3	46
876	Evaluation of a DNA AÎ²42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA AÎ²42 Trimer. Journal of Alzheimer's Disease, 2017, 57, 97-112.	1.2	12
877	Biomarkers in Neurodegenerative Diseases. Advances in Neurobiology, 2017, 15, 491-528.	1.3	69
878	Evaluation of a DNA AÎ²42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA AÎ²42 trimer. Alzheimer's Research and Therapy, 2017, 9, 30.	3.0	17
879	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics, 2017, 14, 35-53.	2.1	128
880	AÎ² vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, AÎ², and microhemorrhages. Neurobiology of Aging, 2017, 49, 86-99.	1.5	20
881	Efficacy and safety of antiâ€amyloidâ€Î² immunotherapy for Alzheimer's disease: a systematic review and network metaâ€analysis. Annals of Clinical and Translational Neurology, 2017, 4, 931-942.	1.7	69
882	Alzheimerâ€™s: Beyond the Brain. , 2017, , 242-273.		2
883	Amyloid Î² Hypothesis in the Development of Therapeutic Agents for Alzheimerâ€™s Disease. , 2017, , 109-143.		5
884	Amyloid Î² Modification: A Key to the Sporadic Alzheimer's Disease?. Frontiers in Genetics, 2017, 8, 58.	1.1	52
885	Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. Frontiers in Neuroscience, 2017, 11, 680.	1.4	108
886	Targeting Transition Metals forÂNeuroprotection inÂAlzheimerâ€™s Disease. , 2017, , 193-215.		2
887	T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimerâ€™s Disease: Potential Pools of New Biomarkers. Journal of Immunology Research, 2017, 2017, 1-17.	0.9	77

#	Article	IF	Citations
888	Potential Treatments for Alzheimerâ€™s Disease. , 2017, , 279-330.		0
889	Drug candidates in clinical trials for Alzheimerâ€™s disease. Journal of Biomedical Science, 2017, 24, 47.	2.6	330
890	Disease modification and Neuroprotection in neurodegenerative disorders. Translational Neurodegeneration, 2017, 6, 25.	3.6	68
891	Achievement of Brain Training Course for the Elderly. Journal of Health Education Research & Development, 2017, 05, .	0.1	0
892	Verification of Preventive Effect of Dual-Task and N-Back Task- Incorporated Music Therapy against Dementia. Neurochemistry & Neuropharmacology: Open Access, 2017, 03, .	0.1	2
894	Human Induced Pluripotent Stem Cells and the Modelling of Alzheimerâ€™s Disease: The Human Brain Outside the Dish. The Open Neurology Journal, 2017, 11, 27-38.	0.4	15
895	The past, present, and future of disease-modifying therapies for Alzheimerâ€™s disease. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2017, 93, 757-771.	1.6	31
896	Current status of vaccines in psychiatryâ€”A narrative review. Asian Journal of Psychiatry, 2018, 31, 112-120.	0.9	6
897	Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4661-4665.	3.3	77
898	Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimer's and Dementia, 2018, 14, 998-1004.	0.4	105
899	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances in Pharmacology, 2018, 82, 293-323.	1.2	67
900	The Vascular Hypothesis of Alzheimerâ€™s Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging. Journal of Alzheimer's Disease, 2018, 63, 35-52.	1.2	90
901	Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation. Molecular Neurobiology, 2018, 55, 9043-9056.	1.9	36
902	Marine derived xyloketal derivatives exhibit anti-stress and anti-ageing effects through HSF pathway in Caenorhabditis elegans. European Journal of Medicinal Chemistry, 2018, 148, 63-72.	2.6	20
903	Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells. Molecular Neurobiology, 2018, 55, 7107-7117.	1.9	56
904	The effect of inhalation of essential oil from Rosmarinus officinalis on scopolamineâ€induced Alzheimer's type dementia model mice. Flavour and Fragrance Journal, 2018, 33, 230-234.	1.2	22
905	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology, 2018, 136, 251-259.	2.0	126
906	A refined concept: Î±-synuclein dysregulation disease. Neurochemistry International, 2018, 119, 84-96.	1.9	24

#	Article	IF	Citations
907	Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimerâ€™s disease, whereas amyloid deposition does not. Alzheimer's Research and Therapy, 2018, 10, 26.	3.0	42
908	The interactions of p53 with tau and AÃŸ as potential therapeutic targets for Alzheimerâ€™s disease. Progress in Neurobiology, 2018, 168, 104-127.	2.8	74
909	Brain Aging and Late-Onset Alzheimerâ€™s Disease: A Matter of Increased Amyloid or Reduced Energy?. Journal of Alzheimer's Disease, 2018, 64, S397-S404.	1.2	17
910	Bridging Multiple Dementias. ACS Chemical Neuroscience, 2018, 9, 636-638.	1.7	0
911	Anti-AÎ² drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease. Analyst, The, 2018, 143, 2204-2212.	1.7	19
912	Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia. International Journal of Geriatric Psychiatry, 2018, 33, e14-e21.	1.3	17
913	Innate immunity in Alzheimerâ€™s disease: the relevance of animal models?. Journal of Neural Transmission, 2018, 125, 827-846.	1.4	16
914	â€œTau immunotherapy: Hopes and hindrancesâ€• Human Vaccines and Immunotherapeutics, 2018, 14, 277-284.	1.4	15
915	Amyloid and immune homeostasis. Immunobiology, 2018, 223, 288-293.	0.8	7
916	Downregulated apoptosis and autophagy after antiâ€AÎ² immunotherapy in Alzheimer's disease. Brain Pathology, 2018, 28, 603-610.	2.1	24
917	Epilepsy as a Network Disorder (2): What can we learn from other network disorders such as dementia and schizophrenia, and what are the implications for translational research?. Epilepsy and Behavior, 2018, 78, 302-312.	0.9	17
918	Membrane Aging as the Real Culprit of Alzheimerâ€™s Disease: Modification of a Hypothesis. Neuroscience Bulletin, 2018, 34, 369-381.	1.5	12
919	Amyloid Î² oligomers (AÎ²Os) in Alzheimerâ€™s disease. Journal of Neural Transmission, 2018, 125, 177-191.	1.4	114
920	MEF2C mRNA expression and cognitive function in Japanese patients with Alzheimer's disease. Psychiatry and Clinical Neurosciences, 2018, 72, 160-167.	1.0	36
921	A symbolic interactionism of dementia: a tangle in â€˜the Alzheimer Conundrumâ€™. Social Theory and Health, 2018, 16, 172-187.	1.0	8
922	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clinical and Translational Science, 2018, 11, 147-152.	1.5	224
923	Alzheimer's disease as oligomeropathy. Neurochemistry International, 2018, 119, 57-70.	1.9	90
924	Present and Future Therapies for Alzheimerâ€™s Disease. , 2018, , .		0

#	Article	IF	Citations
925	Deficient Wnt Signaling and Synaptic Vulnerability in Alzheimerâ€™s Disease: Emerging Roles for the LRP6 Receptor. Frontiers in Synaptic Neuroscience, 2018, 10, 38.	1.3	30
926	Deletion of plasmaPhospholipid Transfer Protein (PLTP)increases microglial phagocytosis and reduces cerebral amyloid-Î² deposition in the J20 mouse model of Alzheimer's disease. Oncotarget, 2018, 9, 19688-19703.	0.8	10
927	Pathogenic Feed-Forward Mechanisms in Alzheimerâ€™s and Parkinsonâ€™s Disease Converge on GSK-3. Brain Plasticity, 2018, 4, 151-167.	1.9	19
928	The Chinese herbal formula Fuzheng Quxie Decoction attenuates cognitive impairment and protects cerebrovascular function in SAMP8 mice. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3037-3051.	1.0	8
929	Spatiotemporal activation of the C/EBPÎ²/Î´-secretase axis regulates the pathogenesis of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12427-E12434.	3.3	21
930	Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release, 2018, 291, 37-64.	4.8	134
931	BACE inhibitors in clinical development for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	1.4	66
932	Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimerâ€™s Disease: A Pilot Study. Current Alzheimer Research, 2018, 15, 820-827.	0.7	9
933	Peptides, Peptidomimetics, and Carbohydrateâ€“Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2018, 9, 1530-1551.	1.7	70
934	A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	20
935	Improved synaptic and cognitive function in aged 3â€¯Ã—â€¯Tg-AD mice with reduced amyloid-Î² after immunotherapy with a novel recombinant 6Aβ15-TF chimeric vaccine. Clinical Immunology, 2018, 193, 12-23.	1.4	4
936	A Novel Association of Polymorphism in theITGA4Gene Encoding the VLA-4Î±4 Subunit with Increased Risk of Alzheimerâ€™s Disease. Mediators of Inflammation, 2018, 2018, 1-8.	1.4	8
938	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. Annual Review of Cell and Developmental Biology, 2018, 34, 545-568.	4.0	99
939	Role of Copper in the Onset of Alzheimerâ€™s Disease Compared to Other Metals. Frontiers in Aging Neuroscience, 2017, 9, 446.	1.7	141
940	The Physiological Roles of Amyloid-Î² Peptide Hint at New Ways to Treat Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 118.	1.7	226
941	Tau Depletion in APP Transgenic Mice Attenuates Task-Related Hyperactivation of the Hippocampus and Differentially Influences Locomotor Activity and Spatial Memory. Frontiers in Neuroscience, 2018, 12, 124.	1.4	24
942	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 254.	1.4	17
943	Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2018, 12, 417.	1.4	34

#	Article	IF	Citations
944	Rate of Î²â€amyloid accumulation varies with baseline amyloid burden: Implications for antiâ€amyloid drug trials. Alzheimer's and Dementia, 2018, 14, 1387-1396.	0.4	16
945	Peptides as Potential Therapeutics for Alzheimerâ€™s Disease. Molecules, 2018, 23, 283.	1.7	45
946	Recent advancements toward therapeutic vaccines against Alzheimerâ€™s disease. Expert Review of Vaccines, 2018, 17, 707-721.	2.0	46
947	In Vivo and In Vitro Characteristics of Radiolabeled Vesamicol Analogs as the Vesicular Acetylcholine Transporter Imaging Agents. Contrast Media and Molecular Imaging, 2018, 2018, 1-14.	0.4	7
948	Alzheimer's disease: Only prevention makes sense. European Journal of Clinical Investigation, 2018, 48, e13005.	1.7	41
949	Safety, tolerability and immunogenicity of an active anti-AÎ²40 vaccine (ABvac40) in patients with Alzheimerâ€™s disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimer's Research and Therapy, 2018, 10, 12.	3.0	72
950	Alzheimerâ€™s disease hypothesis and related therapies. Translational Neurodegeneration, 2018, 7, 2.	3.6	385
951	White matter changes in Alzheimerâ€™s disease: a focus on myelin and oligodendrocytes. Acta Neuropathologica Communications, 2018, 6, 22.	2.4	412
952	Moringa Oleifera Alleviates Homocysteine-Induced Alzheimerâ€™s Disease-Like Pathology and Cognitive Impairments. Journal of Alzheimer's Disease, 2018, 63, 1141-1159.	1.2	57
953	PU.1 regulates Alzheimerâ€™s disease-associated genes in primary human microglia. Molecular Neurodegeneration, 2018, 13, 44.	4.4	111
954	The Domestic Dog as a Model for Human Brain Aging and Alzheimerâ€™s Disease. , 2018, , 177-194.		5
955	Ocular amyloid imaging at the crossroad of Alzheimerâ€™s disease and age-related macular degeneration: implications for diagnosis and therapy. Journal of Neurology, 2019, 266, 1566-1577.	1.8	23
956	Aging, Metabolism, Synaptic Activity, and AÎ² in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 185.	1.7	6
957	Clinical implications of extracellular vesicles in neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2019, 19, 813-824.	1.5	14
958	Antibody-based therapies for Huntingtonâ€™s disease: current status and future directions. Neurobiology of Disease, 2019, 132, 104569.	2.1	17
959	Recent advances of induced pluripotent stem cells application in neurodegenerative diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109674.	2.5	19
960	Emerging links between cell competition and Alzheimer's disease. Journal of Cell Science, 2019, 132, .	1.2	12
961	Microglial motility in Alzheimerâ€™s disease and after AÎ²42 immunotherapy: a human post-mortem study. Acta Neuropathologica Communications, 2019, 7, 174.	2.4	35

#	Article	IF	Citations
962	AÎ²43 in human Alzheimerâ€™s disease: effects of active AÎ²42 immunization. Acta Neuropathologica Communications, 2019, 7, 141.	2.4	20
963	Neuroglia in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, , .	0.8	18
964	Current Updates on the Regulation of Beta-Secretase Movement as a Potential Restorative Focus for Management of Alzheimer's Disease. Protein and Peptide Letters, 2019, 26, 579-587.	0.4	4
965	<scp>PDB</scp>_Amyloid: an extended live amyloid structure list from the <scp>PDB</scp>. FEBS Open Bio, 2019, 9, 185-190.	1.0	7
966	Dietary supplementation with peptides from sesame cake protect Caenorhabditis elegans from polyglutamine-induced toxicity. Journal of Functional Foods, 2019, 54, 199-210.	1.6	7
967	Drug Development for Alzheimerâ€™s Disease: Microglia Induced Neuroinflammation as a Target?. International Journal of Molecular Sciences, 2019, 20, 558.	1.8	99
968	Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology. Molecular Neurobiology, 2019, 56, 5815-5834.	1.9	38
969	A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3636-3648.	2.7	17
970	Tau immunotherapies for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2019, 28, 545-554.	1.9	55
971	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 216-227.	1.8	80
972	A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned. Neurodegenerative Disease Management, 2019, 9, 119-121.	1.2	17
973	Persistent neuropathological effects 14 years following amyloid-Î² immunization in Alzheimerâ€™s disease. Brain, 2019, 142, 2113-2126.	3.7	127
974	Clinical trials of prion disease therapeutics. Current Opinion in Pharmacology, 2019, 44, 53-60.	1.7	21
975	O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. ACS Chemical Neuroscience, 2019, 10, 2209-2221.	1.7	56
976	Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 1677-1686.	1.2	60
977	Personality and Alzheimerâ€™s disease: An integrative review.. Personality Disorders: Theory, Research, and Treatment, 2019, 10, 4-12.	1.0	77
978	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. Journal of the American Geriatrics Society, 2019, 67, 845-847.	1.3	4
979	Senescence in aging and disorders of the central nervous system. Translational Medicine of Aging, 2019, 3, 17-25.	0.6	17

#	Article	IF	Citations
980	Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimerâ€™s disease. Inflammopharmacology, 2019, 27, 663-677.	1.9	276
981	Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 88.	1.7	77
982	The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. Current Opinion in Pharmacology, 2019, 44, 62-75.	1.7	8
983	Effects of Microglial Cytokines on Alzheimerâ€™s Disease-Related Phenomena. Journal of Alzheimer's Disease, 2019, 67, 1021-1034.	1.2	7
984	Active immunization with norovirus P particle-based amyloid-Î² chimeric protein vaccine induces high titers of anti-Aβ antibodies in mice. BMC Immunology, 2019, 20, 9.	0.9	5
985	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimerâ€™s disease pathogenesis. Cellular and Molecular Life Sciences, 2019, 76, 1833-1863.	2.4	75
986	Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain. Frontiers in Aging Neuroscience, 2019, 11, 1.	1.7	214
987	Viral Vector Therapeutics Against Alzheimerâ€™s Disease. , 2019, , 39-44.		1
988	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	1.7	82
989	Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach. Critical Reviews in Therapeutic Drug Carrier Systems, 2019, 36, 373-447.	1.2	12
990	What's New on Alzheimer's Disease? Insights From AD Mouse Models. , 2019, , 431-431.		1
991	Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction. Frontiers in Pharmacology, 2019, 10, 1363.	1.6	57
992	Amyloidâ€Î² oligomers suppress subunitâ€specific glutamate receptor increase during LTP. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 797-808.	1.8	14
993	A critical appraisal of amyloid-Î²-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	4.9	666
994	Treating Alzheimer's disease by targeting iron. British Journal of Pharmacology, 2019, 176, 3622-3635.	2.7	71
995	Brains for Dementia Research: The Importance of Cohorts in Brain Banking. Neuroscience Bulletin, 2019, 35, 289-294.	1.5	6
996	Amyloidâ€Î² immunotherapy for alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	2.8	126
997	Applications of fluorine-containing amino acids for drug design. European Journal of Medicinal Chemistry, 2020, 186, 111826.	2.6	150

#	Article	IF	Citations
998	Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2020, 134, 104644.	2.1	33
999	Active Immunotherapy to Prevent Alzheimer Diseaseâ€"A DNA Amyloid Î² 1-42 Trimer Vaccine. JAMA Neurology, 2020, 77, 289.	4.5	9
1000	Alzheimerâ€™s/Vascular Spectrum Dementia: Classification in Addition to Diagnosis. Journal of Alzheimer's Disease, 2020, 73, 63-71.	1.2	47
1001	Alzheimerâ€™s disease beyond amyloid: strategies for future therapeutic interventions. BMJ, The, 2020, 371, m3684.	3.0	36
1002	The Role of Mitochondrial Calcium Homeostasis in Alzheimerâ€™s and Related Diseases. International Journal of Molecular Sciences, 2020, 21, 9153.	1.8	54
1003	Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam. Neurobiology of Aging, 2020, 96, 79-86.	1.5	16
1004	Adiponectin Paradox as a Therapeutic Target in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 1249-1253.	1.2	9
1005	Brain angiotensin II and angiotensin IV receptors as potential Alzheimerâ€™s disease therapeutic targets. GeroScience, 2020, 42, 1237-1256.	2.1	28
1006	Animal Models of Parkinsonâ€™s Disease: Are They Useful or Not?. Journal of Parkinson's Disease, 2020, 10, 1335-1342.	1.5	22
1007	Copper Toxicity Links to Pathogenesis of Alzheimerâ€™s Disease and Therapeutics Approaches. International Journal of Molecular Sciences, 2020, 21, 7660.	1.8	64
1008	Computational Investigation of Gantenerumab and Crenezumab Recognition of AÎ² Fibrils in Alzheimerâ€™s Disease Brain Tissue. ACS Chemical Neuroscience, 2020, 11, 3233-3244.	1.7	12
1009	PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells . International Journal of Nanomedicine, 2020, Volume 15, 6779-6789.	3.3	18
1010	Vaccination against Î²-Amyloid as a Strategy for the Prevention of Alzheimerâ€™s Disease. Biology, 2020, 9, 425.	1.3	26
1011	The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 583884.	1.7	14
1012	Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12090.	1.8	3
1013	New Insights Into Drug Discovery Targeting Tau Protein. Frontiers in Molecular Neuroscience, 2020, 13, 590896.	1.4	78
1014	Combination Drug Therapy for the Management of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3272.	1.8	110
1015	Collagen hydrogel confinement of Amyloid-Î² (AÎ²) accelerates aggregation and reduces cytotoxic effects. Acta Biomaterialia, 2020, 112, 164-173.	4.1	11

#	Article	IF	Citations
1016	Allosteric modulation of AMPA receptors counteracts Tau-related excitotoxic synaptic signaling and memory deficits in stress- and AÎ²-evoked hippocampal pathology. Molecular Psychiatry, 2021, 26, 5899-5911.	4.1	12
1017	Circular Dichroism Spectroscopy Identifies the Î²-Adrenoceptor Agonist Salbutamol As a Direct Inhibitor of Tau Filament Formation in Vitro. ACS Chemical Neuroscience, 2020, 11, 2104-2116.	1.7	16
1018	Amyloidâ€Îβ plaques may be reduced in advanced stages of cerebral amyloid angiopathy in the elderly. Neuropathology, 2020, 40, 474-481.	0.7	3
1019	Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. Frontiers in Cellular Neuroscience, 2020, 14, 129.	1.8	35
1020	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs, 2020, 29, 333-348.	1.9	94
1021	Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 1992.	1.8	25
1022	The role of the immune system in driving neuroinflammation. Brain and Neuroscience Advances, 2020, 4, 239821281990108.	1.8	42
1023	Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases. , 2020, , 29-53.		2
1024	Current clinical approaches in neurodegenerative diseases. , 2020, , 79-124.		1
1025	Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews, 2020, 296, 169-190.	2.8	56
1026	Yeast-Based AÎ²1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimerâ€™s Disease Transgenic Mice. Vaccines, 2020, 8, 351.	2.1	7
1027	Invited Review â€“ Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. Neuropathology and Applied Neurobiology, 2020, 46, 623-640.	1.8	20
1028	Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. Bioorganic Chemistry, 2020, 97, 103649.	2.0	61
1029	Traitement de la maladie dâ€™AlzheimerÂ: une lueur au bout du tunnelÂ?. Pratique Neurologique - FMC, 2020, 11, 46-48.	0.1	0
1030	Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiology of Disease, 2020, 139, 104823.	2.1	20
1031	Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 2020, 27, 18.	2.6	453
1032	Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses. Frontiers in Immunology, 2019, 10, 2980.	2.2	7
1033	Polymeric Nanoparticles for Nasal Drug Delivery to the Brain: Relevance to Alzheimer's Disease. Advanced Therapeutics, 2021, 4, 2000076.	1.6	61

#	Article	IF	Citations
1034	Principles and requirements for stroke recovery science. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 471-485.	2.4	14
1035	Detection and monitoring of the neuroprotective behavior of curcumin micelles based on an AIEgen probe. Journal of Materials Chemistry B, 2021, 9, 731-745.	2.9	7
1036	Partial Inhibition of Mitochondrial Complex I Reduces Tau Pathology and Improves Energy Homeostasis and Synaptic Function in 3xTg-AD Mice. Journal of Alzheimer's Disease, 2021, 79, 335-353.	1.2	22
1037	Is Î³-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. Journal of Biological Chemistry, 2021, 296, 100489.	1.6	32
1038	Microvascular Alterations in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2020, 14, 618986.	1.8	41
1039	Experimental Approach to Alzheimerâ€™s Disease with Emphasis on Insulin Resistance in the Brain. , 2021, , 1-52.		4
1040	Transcriptional downregulation of FAM3C/ILEI in the Alzheimerâ€™s brain. Human Molecular Genetics, 2021, 31, 122-132.	1.4	14
1041	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimerâ€™s Disease: Are Immunotherapies Effective or Off-Target?. Neuroscientist, 2022, 28, 254-270.	2.6	9
1042	Alzheimer's disease research: past approaches and future directions. British Journal of Neuroscience Nursing, 2021, 17, 34-39.	0.1	0
1043	New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 3363-3373.	1.6	4
1044	Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. Clinical and Translational Medicine, 2021, 11, e397.	1.7	22
1045	Intracellular amyloid hypothesis for ultraâ€early phase pathology of Alzheimer's disease. Neuropathology, 2021, 41, 93-98.	0.7	21
1046	Alternative Targets to Fight Alzheimerâ€™s Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	1.8	16
1047	Alzheimerâ€™s Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. Current Neuropharmacology, 2021, 19, 498-512.	1.4	16
1048	Amyloids: The History of Toxicity and Functionality. Biology, 2021, 10, 394.	1.3	12
1049	The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimerâ€™s. Expert Opinion on Therapeutic Targets, 2021, 25, 401-414.	1.5	20
1050	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	2.0	57
1051	Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. Journal of Alzheimer's Disease, 2021, 82, 631-646.	1.2	10

#	Article	IF	Citations
1052	Aducanumab and disease modifying treatments for Alzheimer's disease. Progress in Neurology and Psychiatry, 2021, 25, 4-6.	0.4	7
1053	Cell stiffness and ROS level alterations in living neurons mediated by Î²-amyloid oligomers measured by scanning ion-conductance microscopy.. Microscopy and Microanalysis, 2021, 27, 500-502.	0.2	4
1054	Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimerâ€™s Disease. Pharmaceutics, 2021, 13, 1002.	2.0	4
1055	Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta. Laboratory Investigation, 2021, 101, 1605-1617.	1.7	31
1056	New insights in drug development for Alzheimer's disease based on microglia function. Biomedicine and Pharmacotherapy, 2021, 140, 111703.	2.5	18
1057	The degree of frailty as a translational measure of health in aging. Nature Aging, 2021, 1, 651-665.	5.3	104
1058	Neuroinflammatory Signaling in the Pathogenesis of Alzheimerâ€™s Disease. Current Neuropharmacology, 2022, 20, 126-146.	1.4	28
1059	Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. Journal of the Korean Neurological Association, 2021, 39, 134-140.	0.0	2
1060	The FDA Approves Aducanumab for Alzheimerâ€™s Disease, Raising Important Scientific Questions1. Journal of Alzheimer's Disease, 2021, 82, 881-882.	1.2	18
1061	Effect of pyrrolo[3,4-d]pyridazinone derivatives in neuroinflammation induced by preincubation with lipopolysaccharide or coculturing with microglia-like cells. Biomedicine and Pharmacotherapy, 2021, 141, 111878.	2.5	4
1062	US Food and Drug Administration Approval of Aducanumabâ€”Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. JAMA Neurology, 2021, 78, 1307.	4.5	30
1063	Network activity changes in the pathophysiology of Alzheimerâ€™s disease: the role of aging and early entorhinal cortex dysfunction. Metabolic Brain Disease, 2022, 37, 289-298.	1.4	2
1064	The Impact of Ageing on the CNS Immune Response in Alzheimerâ€™s Disease. Frontiers in Immunology, 2021, 12, 738511.	2.2	11
1065	Amyloid-Î² and Î±-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. Frontiers in Neuroscience, 2021, 15, 733857.	1.4	25
1066	Multi-mechanical waves against Alzheimerâ€™s disease pathology: a systematic review. Translational Neurodegeneration, 2021, 10, 36.	3.6	10
1067	Roles of microglia in Alzheimerâ€™s disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. Biochemical Pharmacology, 2021, 192, 114754.	2.0	24
1068	Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies. Free Radical Biology and Medicine, 2021, 174, 281-304.	1.3	3
1069	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	2.0	11

#	Article	IF	Citations
1071	NGF and BDNF Gene Therapy for Alzheimerâ€™s Disease. , 2016, , 33-64.		4
1072	Immunotherapy for Alzheimerâ€™s Disease: DNA- and Protein-Based Epitope Vaccines. Methods in Molecular Biology, 2014, 1143, 259-281.	0.4	11
1073	The Aged Dog as a Natural Model of Alzheimerâ€™s Disease Progression. , 2017, , 69-92.		2
1074	Alzheimer-Demenz. , 2011, , 47-72.		2
1075	Neuroimaging Findings in Mild Cognitive Impairment. , 2014, , 271-307.		2
1076	Is there room for Darwinian medicine and the hygiene hypothesis in Alzheimer pathogenesis?. , 2009, , 257-278.		1
1077	Drug Development for Neurodegenerative Diseases. , 2015, , 183-216.		5
1078	The Role of AÎ² and Tau Oligomers in the Pathogenesis of Alzheimerâ€™s Disease. , 2012, , 135-188.		5
1079	Oligodendroglial Cells in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1175, 325-333.	0.8	59
1081	Presentation and Clinical Management of Dementia. , 2010, , 392-401.		2
1082	Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity. Yearbook of Neurology and Neurosurgery, 2010, 2010, 12-13.	0.0	1
1087	Examination on Brain Training Method: Effects of n-back task and dual-task. F1000Research, 0, 6, 116.	0.8	1
1088	Resolving the paradox for protein aggregation diseases: a common mechanism for aggregated proteins to initially attack membranes without needing aggregates. F1000Research, 0, 2, 221.	0.8	10
1089	Resolving the paradox for protein aggregation diseases: NMR structure and dynamics of the membrane-embedded P56S-MSP causing ALS imply a common mechanism for aggregation-prone proteins to attack membranes. F1000Research, 2013, 2, 221.	0.8	7
1090	Immunotherapies Targeting Î± -Synuclein in Parkinson Disease. , 2020, 37, 375-379.		4
1091	New treatment modalities in Alzheimer's disease. World Journal of Clinical Cases, 2019, 7, 1764-1774.	0.3	12
1092	T Cells Specifically Targeted to Amyloid Plaques Enhance Plaque Clearance in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2010, 5, e10830.	1.1	75
1093	Immunomodulation Targeting Abnormal Protein Conformation Reduces Pathology in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2010, 5, e13391.	1.1	46

#	Article	IF	Citations
1094	Unfolding of the Amyloid Î²-Peptide Central Helix: Mechanistic Insights from Molecular Dynamics Simulations. PLoS ONE, 2011, 6, e17587.	1.1	26
1095	A Cyclic Undecamer Peptide Mimics a Turn in Folded Alzheimer Amyloid Î² and Elicits Antibodies against Oligomeric and Fibrillar Amyloid and Plaques. PLoS ONE, 2011, 6, e19110.	1.1	13
1096	Blockade of Gap Junction Hemichannel Suppresses Disease Progression in Mouse Models of Amyotrophic Lateral Sclerosis and Alzheimer's Disease. PLoS ONE, 2011, 6, e21108.	1.1	126
1097	Abnormal Cognition, Sleep, EEG and Brain Metabolism in a Novel Knock-In Alzheimer Mouse, PLB1. PLoS ONE, 2011, 6, e27068.	1.1	115
1098	Prophylaxis and Treatment of Alzheimer's Disease by Delivery of an Adeno-Associated Virus Encoding a Monoclonal Antibody Targeting the Amyloid Beta Protein. PLoS ONE, 2013, 8, e57606.	1.1	22
1099	Increased Levels of Antigen-Bound Î²-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients. PLoS ONE, 2013, 8, e68996.	1.1	45
1100	Investigating Interventions in Alzheimer's Disease with Computer Simulation Models. PLoS ONE, 2013, 8, e73631.	1.1	28
1101	Development of a New DNA Vaccine for Alzheimer Disease Targeting a Wide Range of AÎ² Species and Amyloidogenic Peptides. PLoS ONE, 2013, 8, e75203.	1.1	25
1102	Anti-Human Î±-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-Î±-Synuclein Rat Model of Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0116841.	1.1	68
1103	DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMERâ€™S DISEASE. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-7.	1.5	65
1104	Establishment of a Drosophila AD model. Journal of Biological Methods, 2016, 3, e43.	1.0	3
1105	Alzheimerâ€™s disease: amyloid-based pathogenesis and potential therapies. Cell Stress, 2018, 2, 150-161.	1.4	27
1106	AÎ² Plaques. Free Neuropathology, 2020, 1, .	2.4	21
1107	Alzheimerâ€™s Disease â€“ The Importance of Early Detection. European Neurological Review, 2008, 3, 18.	0.5	7
1108	Combination Drug Therapy for the Treatment of Alzheimerâ€™s Disease. European Neurological Review, 2012, 7, 92.	0.5	5
1109	Idolizing the clearance of Amyloid-Î² by microglia. Annals of Translational Medicine, 2016, 4, 536-536.	0.7	3
1110	Therapeutic Approaches to Alzheimerâ€™s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. Current Pharmaceutical Design, 2019, 25, 2555-2568.	0.9	25
1111	CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study. Current Alzheimer Research, 2013, 10, 742-753.	0.7	73

#	Article	IF	Citations
1112	Reduced Alzheimerâ€™s Disease Pathology by St. Johnâ€™s Wort Treatment is Independent of Hyperforin and Facilitated by ABCC1 and Microglia Activation in Mice. Current Alzheimer Research, 2013, 10, 1057-1069.	0.7	82
1113	Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xTg Mouse Model of Alzheimerâ€™s Disease. Current Alzheimer Research, 2014, 11, 655-663.	0.7	14
1114	How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease. Current Alzheimer Research, 2011, 8, 156-163.	0.7	55
1115	Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications. Current Topics in Medicinal Chemistry, 2013, 13, 1853-1863.	1.0	12
1116	Emerging Promise of Immunotherapy for Alzheimerâ€™s Disease: A New Hope for the Development of Alzheimerâ€™s Vaccine. Current Topics in Medicinal Chemistry, 2020, 20, 1214-1234.	1.0	22
1117	The Amyloid Cascade Hypothesis in Alzheimerâ€™s Disease: Itâ€™s Time to Change Our Mind. Current Neuropharmacology, 2017, 15, 926-935.	1.4	253
1118	Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies. CNS and Neurological Disorders - Drug Targets, 2010, 9, 727-740.	0.8	21
1119	Drug Targets from Genetics: Alpha-Synuclein. CNS and Neurological Disorders - Drug Targets, 2011, 10, 712-723.	0.8	9
1120	Advances in Imaging: Brain Tumors to Alzheimerâ€™s Disease. The Bangkok Medical Journal, 2015, 10, 83-97.	0.2	1
1121	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	6
1122	Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behavioural Neurology, 2009, 21, 117-28.	1.1	125
1123	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment, 2017, 21, 1-192.	1.3	37
1124	Effect of Amyloid-Î² Monomers on Lipid Membrane Mechanical Parametersâ€“Potential Implications for Mechanically Driven Neurodegeneration in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 18.	1.8	19
1125	Alzheimer's - Looking beyond plaques. F1000 Medicine Reports, 2011, 3, 24.	2.9	17
1126	Progress on AÎ²-Targeted Therapeutic Strategies for Alzheimerâ€²s Disease*. Progress in Biochemistry and Biophysics, 2012, 39, 734-740.	0.3	2
1127	Alzheimerâ€™s Disease: Current Status of Etiopathogenesis and Therapeutic Strategies. Pakistan Journal of Biological Sciences, 2011, 14, 257-272.	0.2	27
1128	Towards defining the Mechanisms of Alzheimer's disease based on a contextual analysis of molecular pathways. AIMS Genetics, 2016, 03, 025-048.	1.9	3
1129	The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. Indian Journal of Psychiatry, 2009, 51, 12.	0.4	68

#	Article	IF	Citations
1130	Alzheimerâ€²s disease: Unique markers for diagnosis & new treatment modalities. Indian Journal of Medical Research, 2015, 142, 369.	0.4	13
1131	Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition. Neural Regeneration Research, 2018, 13, 1719.	1.6	59
1132	Kai Xin San ameliorates scopolamine-induced cognitive dysfunction. Neural Regeneration Research, 2019, 14, 794.	1.6	28
1133	Early active immunization with AÎ² _{3â€“10}-KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice. Neural Regeneration Research, 2020, 15, 519.	1.6	12
1134	Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats. Indian Journal of Endocrinology and Metabolism, 2012, 16, 601.	0.2	13
1135	Virus-like particle based vaccines for Alzheimer disease. Hum Vaccin, 2010, 6, 926-30.	2.4	21
1136	A Tipping Point for Alzheimerâ€™s Disease Research. , 2012, 02, .		1
1137	Novel Therapeutic Approaches to Treat Alzheimerâ€™s Disease and Memory Disorders. Journal of Proteomics and Bioinformatics, 2008, 01, 464-476.	0.4	6
1138	Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimerâ€™s Disease Pathogenesis. Molecular Biology, 2021, 55, 670-682.	0.4	10
1139	Past, present and future of therapeutic strategies against amyloid-Î² peptides in Alzheimerâ€™s disease: a systematic review. Ageing Research Reviews, 2021, 72, 101496.	5.0	131
1141	ã‚¢ãƒ«ãƒ„ãƒã‚¤ãƒžãƒ¼ç—…ã®æˆ‘ãŒå›½ã•æ²»ç™‚. JuntendoÌ„ Igaku, 2010, 56, 447-451.	0.1	0
1142	MOLECULAR AND CELLULAR MECHANISMS OF ALZHEIMERÂ’S DISEASE DEVELOPMENT. Fiziolohichnyi Zhurnal (Kiev, Ukraine: 1994), 2010, 56, 127-142.	0.1	0
1143	Synapses and Alzheimersâ€™s Disease: Effect of Immunotherapy?. , 2011, , 269-287.		0
1144	Cognitive Deficits in Neurodegenerative Disorders: Parkinsonâ€™s Disease and Alzheimerâ€™s Disease. Advances in Neurobiology, 2011, , 243-292.	1.3	0
1145	The Neuroimmunology of Cortical Disease (Dementia, Epilepsy, and Autoimmune Encephalopathies). , 2011, , 275-290.		1
1146	Future treatments of memory loss. , 2011, , 199-213.		0
1147	Vaccination in the Elderly. , 2012, , 157-174.		1
1148	Therapeutics of Alzheimerâ€™s Disease. , 0, , .		1

#	Article	IF	Citations
1149	Epigenetic Mechanisms Regulating Memory Formation in Health and Disease. Research and Perspectives in Neurosciences, 2012, , 97-104.	0.4	0
1150	Antidementiva. , 2012, , 713-731.		0
1151	In Search of Therapeutic Solutions for Alzheimerâ€™s Disease. , 0, , .		0
1152	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.		0
1153	The Current Status of Alzheimer's Disease Treatment. Frontiers in Neuroscience, 2012, , 117-161.	0.0	0
1154	Immunomodulation. , 2013, , 269-287.		1
1155	ã‚¢ãƒ«ãƒ„ãƒã‚¤ãƒžãƒ¼ç—…ã«å¯¾ã™ã‚‹ãƒ¯ã‚¯ãƒãƒ³ç™‚æ³•. Juntendo Medical Journal, 2013, 59, 36-40.	0.1	0
1156	Tempo de cÃ©rebro. Estudos Avancados, 2013, 27, 07-22.	0.2	2
1157	Essais thÃ©rapeutiques de phase I dans la maladie dâ€™Alzheimer. , 2013, , 357-363.		0
1158	Alzheimer Disease. , 2013, , .		0
1159	Merits and Demerits of Vaccination for Patients with Neurological Diseases. Juntendo Medical Journal, 2014, 60, 470-470.	0.1	0
1160	Antidementiva. , 2014, , 381-391.		0
1161	Experimental Approach to Alzheimer Disease. , 2014, , 2025-2045.		0
1162	Immunotherapy Applied to Neuropsychiatric Disorders: A New Perspective. , 2014, 4, .		0
1163	Merits and Demerits of Vaccination for Patients with Neurological Diseases. Juntendo Medical Journal, 2014, 60, s53-s59.	0.1	0
1164	Neurodegeneration and Its Prevention. , 2014, , 1-10.		0
1165	The 2013 Incentive Award of the Okayama Medical Association in Neuroscience (2013 Niimi Prize). Okayama Igakkai Zasshi, 2014, 126, 99-102.	0.0	0
1166	Alzheimerâ€™s Disease: Current and Future Treatments. A Review. International Journal of Medical Students, 2014, 2, 56-63.	0.2	3

#	Article	IF	Citations
1167	Proceso inflamatorio en la enfermedad de Alzheimer. Papel de las citoquinas. , 2014, , 121-156.		0
1168	Genomics Reveals Similar and Dissimilar Pathogenesis between Alzheimerâ€™s and Parkinsonâ€™s Diseases. Biological Systems, Open Access, 2015, 05, .	0.1	0
1169	Antidementiva. , 2015, , 389-398.		0
1170	Gene Therapy for Alzheimerâ€™s Disease. , 2015, , 1217-1232.		0
1171	Frontiers in Clinical Drug Research - Alzheimer Disorders. , 2015, , .		0
1173	The Brave New Brain World. Journal of Advanced Medical Sciences and Applied Technologies, 2015, 1, 1.	0.3	0
1175	Unproven Hypotheses on the Cause of Alzheimerâ€™s. , 2016, , 39-48.		0
1176	Antidementiva. , 2016, , 293-299.		0
1178	Antidementiva. , 2017, , 291-297.		0
1179	Antidementiva. , 2018, , 345-352.		0
1180	Therapeutic Vaccines Targeting Alzheimerâ€™s Disease. , 2019, , 9-20.		1
1181	Antidementiva. , 2019, , 461-469.		0
1182	New strategies for diagnosis and treatment of Alzheimer's disease: monoclonal antibodies to beta-amyloid. Medical Alphabet, 2019, 1, 35-42.	0.0	4
1187	FAM3C in Alzheimer's disease. , 2020, , 293-307.		0
1190	Circulating asymmetric dimethylarginine and cognitive decline: A 4â€year followâ€up study of the 1936 Aberdeen Birth Cohort. International Journal of Geriatric Psychiatry, 2020, 35, 1181-1188.	1.3	8
1191	for Disease-Modifying Agents in Parkinsonâ€™s. Neuromethods, 2021, , 161-175.	0.2	0
1193	Psychopathology of Dementia: Psychologyâ€™s Pivotal Role. European Journal of Medical and Health Sciences, 2021, 3, 61-69.	0.1	0
1194	Deep Learning-Based Screening Test for Cognitive Impairment Using Basic Blood Test Data for Health Examination. Frontiers in Neurology, 2020, 11, 588140.	1.1	10

#	Article	IF	Citations
1195	Immunotherapy Targeting Amyloid-ÃŸ Peptides in Alzheimerâ€™s Disease. , 0, , 23-49.		3
1196	Dementia: Alzheimerâ€™s Disease. , 2021, , 397-457.		0
1198	Genomics of Alzheimerâ€™s disease. , 2020, , 3-18.		0
1199	Molecular Modelling Based Design and Synthesis of Donepezil Like Derivatives As Acetylcholinesterase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	1
1202	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
1218	Deep brain stimulation: a novel strategy for treating Alzheimer's disease. Innovations in Clinical Neuroscience, 2012, 9, 10-7.	0.1	196
1219	Immunity and inflammation in neurodegenerative diseases. American Journal of Neurodegenerative Disease, 2013, 2, 89-107.	0.1	83
1220	Alzheimer's disease and immunotherapy. , 2013, 4, 210-20.		11
1222	A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta. Neural Regeneration Research, 2013, 8, 2581-90.	1.6	4
1223	Novel immunological approaches for the treatment of Alzheimer's disease. Chinese Journal of Contemporary Neurology and Neurosurgery, 2014, 14, 139-151.	0.0	0
1225	Role of neovibsanin scaffold in preservation of spatial cognitive functions of rats with chronic epilepsy. International Journal of Clinical and Experimental Pathology, 2015, 8, 8692-8.	0.5	0
1226			

#	Article	IF	Citations
1234	Innate Immunity and Cell Death in Alzheimer's Disease. ASN Neuro, 2021, 13, 175909142110519.	1.5	19
1235	Knowledge of Dementia Treatment : Prospects for Disease-modifying Therapy in Alzheimer's Disease. Japanese Journal of Neurosurgery, 2021, 30, 840-844.	0.0	0
1236	Antidementiva. , 2021, , 231-239.		1
1237	Histopathological correlates of haemorrhagic lesions on ex vivo magnetic resonance imaging in immunized Alzheimerâ€™s disease cases. Brain Communications, 2022, 4, fcac021.	1.5	7
1238	Fighting fire with fire: The immune system might be key in our fight against Alzheimerâ€™s disease. Drug Discovery Today, 2022, 27, 1261-1283.	3.2	10
1239	A Review of the Current Mammalian Models of Alzheimerâ€™s Disease and Challenges That Need to Be Overcome. International Journal of Molecular Sciences, 2021, 22, 13168.	1.8	31
1240	DNA vaccines targeting amyloid-Î² oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 2305.	1.6	6
1241	Exercise-Eating Pattern and Social Inclusion (EES) is an Effective Modulator of Pathophysiological Hallmarks of Alzheimerâ€™s Disease. , 0, , .		0
1242	Delivery of Intravenously Administered Antibodies Targeting Alzheimerâ€™s Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis. Pharmaceutics, 2022, 14, 411.	2.0	12
1243	Safety and Efficacy of Monoclonal Antibodies for Alzheimerâ€™s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials. Journal of Alzheimer's Disease, 2022, 87, 101-129.	1.2	31
1244	Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice. Frontiers in Pharmacology, 2022, 13, 864591.	1.6	5
1245	Drug Development for Alzheimerâ€™s Disease: An Historical Perspective. , 2022, , 25-33.		0
1246	Immunotherapy for Alzheimerâ€™s disease: targeting Î²-amyloid and beyond. Translational Neurodegeneration, 2022, 11, 18.	3.6	75
1247	Combined Modeling Study of the Binding Characteristics of Natural Compounds, Derived from Psoralea Fruits, to Î²-Amyloid Peptide Monomer. International Journal of Molecular Sciences, 2022, 23, 3546.	1.8	2
1248	Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes. CNS and Neurological Disorders - Drug Targets, 2021, 21, .	0.8	0
1255	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. Neurotherapeutics, 2022, 19, 209-227.	2.1	36
1256	Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.. Free Neuropathology, 2021, 2, .	2.4	9
1259	War-related mental health issues and need for yoga intervention studies: A scoping review. International Journal of Yoga, 2021, 14, 175.	0.4	2

#	Article	IF	Citations
1260	Reconsideration of Alzheimerâ€™s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability. Journal of Alzheimer's Disease Reports, 2022, 6, 207-210.	1.2	1
1261	Association Between Wine Consumption and Cognitive Decline in Older People: A Systematic Review and Meta-Analysis of Longitudinal Studies. Frontiers in Nutrition, 2022, 9, .	1.6	6
1262	Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathologica, 2022, 144, 143-153.	3.9	18
1265	ROCKs as a potential drug target to combat Alzheimer's disease. , 2022, , 409-433.		1
1266	A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?. Journal of the Neurological Sciences, 2022, 438, 120294.	0.3	9
1267	Shared pathophysiology: Understanding stroke and Alzheimerâ€™s disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	0.6	9
1268	Anti-Amyloid-Î² Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	0
1270	Innate Immune Cell Death in Neuroinflammation and Alzheimerâ€™s Disease. Cells, 2022, 11, 1885.	1.8	49
1271	Overview of therapeutic targets in management of dementia. Biomedicine and Pharmacotherapy, 2022, 152, 113168.	2.5	15
1273	Emerging Roles of T Helper Cells in Non-Infectious Neuroinflammation: Savior or Sinner. Frontiers in Immunology, 0, 13, .	2.2	2
1274	Immune Response at the Crossroads of Atherosclerosis and Alzheimer's Disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
1276	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimerâ€™s disease: Current trends and future perspectives. Frontiers in Neuroscience, 0, 16, .	1.4	16
1277	Anodal and cathodal transcranial direct current stimulations of prefrontal cortex in a rodent model of Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
1278	Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 9777.	1.8	22
1279	Alzheimerâ€™s disease: Pathophysiology and dental pulp stem cells therapeutic prospects. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
1280	Combination Therapy for the Treatment of Alzheimerâ€™s Disease: Recent Progress and Future Prospects. Current Topics in Medicinal Chemistry, 2022, 22, 1849-1867.	1.0	3
1281	Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. Chemical Science, 2022, 13, 13657-13689.	3.7	25
1282	Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. Journal of Experimental Pharmacology, 0, Volume 14, 331-352.	1.5	8

#	Article	IF	Citations
1284	Amyloid Beta in Aging and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 12924.	1.8	50
1285	The significance of glycolysis index and its correlations with immune infiltrates in Alzheimerâ€™s disease. Frontiers in Immunology, 0, 13, .	2.2	5
1286	Morphometric imaging biomarker identifies Alzheimerâ€™s disease even among mixed dementia patients. Scientific Reports, 2022, 12, .	1.6	2
1287	Pharmacological Treatment of Alzheimerâ€™s Disease. Advances in Biological Psychiatry, 2012, , 122-167.	0.2	3
1288	Anti-dementia Medications: Classification, Indications, and Differential Indications. , 2022, , 2637-2647.		0
1289	Amyloidogenesis: What Do We Know So Far?. International Journal of Molecular Sciences, 2022, 23, 13970.	1.8	5
1290	Tau immunotherapy in Alzheimerâ€™s disease and progressive supranuclear palsy. International Immunopharmacology, 2022, 113, 109445.	1.7	5
1292	Haemorheologic Enhancement of Cerebral Perfusion Improves Oxygen Supply and Reduces AÎ² Plaques Deposition in a Mouse Model of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2022, , 335-340.	0.8	2
1293	Amyloid Cascade Hypothesis for the Treatment of Alzheimerâ€™s Disease: Progress and Challenges. , 2022, 13, 1745.		21
1295	Alzheimerâ€™s Disease: Clinical Trials and the Amyloid Hypothesis. Annals of the Academy of Medicine, Singapore, 2011, 40, 304-306.	0.2	2
1296	Experimental Approach to Alzheimerâ€™s Disease with Emphasis on Insulin Resistance in the Brain. , 2022, , 1657-1708.		0
1297	Molecular imaging of the association between serotonin degeneration and beta-amyloid deposition in mild cognitive impairment. NeuroImage: Clinical, 2023, 37, 103322.	1.4	5
1298	Experimental approaches for altering the expression of Abetaâ€degrading enzymes. Journal of Neurochemistry, 2023, 164, 725-763.	2.1	4
1299	Dementia and Mild Neurocognitive Disorders. , 2022, , .		0
1300	Animal Models of Amyloid/PS-1 Pathology. , 2011, , 15-38.		0
1301	Neurodegenerative Erkrankungen. , 2022, , 559-568.		1
1302	Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review. IET Nanobiotechnology, 2023, 17, 154-170.	1.9	4
1303	Amyloid â€“Î² pathology in Alzheimerâ€™s disease: A nano delivery approach. Vibrational Spectroscopy, 2023, 126, 103510.	1.2	3

#	Article	IF	Citations
1304	Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Disease-a-Month, 2023, 69, 101547.	0.4	4
1305	Pathogenesis of Alzheimerâ€™s Disease. , 2022, , 1709-1728.		0
1306	Revealing the Nanoarchitectonics of Amyloid Î²â€Aggregation on Twoâ€Dimensional Biomimetic Membranes by Surfaceâ€Enhanced Infrared Absorption Spectroscopy. ChemistryOpen, 2023, 12, .	0.9	3
1307	Lessons from antiamyloid-Î² immunotherapies in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 267-291.	1.0	7
1308	Aducanumabâ€”Hope or Disappointment for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 4367.	1.8	19
1309	Neuroinflammation and neuroimmunology in Alzheimer's disease: The role of Tâ€lymphocytes in Alzheimer's disease. Clinical and Experimental Neuroimmunology, 2023, 14, 92-99.	0.5	3
1310	Alzheimerâ€™s Disease from the Amyloidogenic Theory to the Puzzling Crossroads between Vascular, Metabolic and Energetic Maladaptive Plasticity. Biomedicines, 2023, 11, 861.	1.4	1
1311	Exercise suppresses neuroinflammation for alleviating Alzheimerâ€™s disease. Journal of Neuroinflammation, 2023, 20, .	3.1	19
1312	Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3Î²?. Frontiers in Neuroscience, 0, 17, .	1.4	5
1313	Neurodegenerative diseases. , 2023, , 563-598.		0
1317	Step by Step Toward an Amyloid Beta Peptide-Based Hypothesis of Alzheimerâ€™s Disease. , 2023, , 135-166.		0
1318	Ignorance or Conspiracy? Or Just an Amyloid Firewall that Blocks Alternative Ideas?. , 2023, , 185-226.		0
1328	Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimerâ€™s Disease. BioDrugs, 2024, 38, 5-22.	2.2	5
1332	Demenzen. , 2023, , 597-606.		0